<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="pmc-domain-id">3054</journal-id><journal-id journal-id-type="pmc-domain">microorg</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7465679</article-id><article-id pub-id-type="pmcid-ver">PMC7465679.1</article-id><article-id pub-id-type="pmcaid">7465679</article-id><article-id pub-id-type="pmcaiid">7465679</article-id><article-id pub-id-type="pmid">32784615</article-id><article-id pub-id-type="doi">10.3390/microorganisms8081201</article-id><article-id pub-id-type="publisher-id">microorganisms-08-01201</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Leishmania</italic> Immunity: Advancing Immunotherapy and Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ikeogu</surname><given-names initials="NM">Nnamdi M.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01201">1</xref><xref rid="c1-microorganisms-08-01201" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akaluka</surname><given-names initials="GN">Gloria N.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01201">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Edechi</surname><given-names initials="CA">Chidalu A.</given-names></name><xref ref-type="aff" rid="af2-microorganisms-08-01201">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salako</surname><given-names initials="ES">Enitan S.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01201">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onyilagha</surname><given-names initials="C">Chukwunonso</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01201">1</xref><xref ref-type="aff" rid="af3-microorganisms-08-01201">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barazandeh</surname><given-names initials="AF">Aida F.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01201">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uzonna</surname><given-names initials="JE">Jude E.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01201">1</xref><xref rid="c1-microorganisms-08-01201" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-microorganisms-08-01201"><label>1</label>Department of Immunology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0T5, Canada; <email>akalukag@myumanitoba.ca</email> (G.N.A.); <email>salakoe@myumanitoba.ca</email> (E.S.S.); <email>chukwunonso.onyilagha@canada.ca</email> (C.O.); <email>feizbara@myumanitoba.ca</email> (A.F.B.)</aff><aff id="af2-microorganisms-08-01201"><label>2</label>Department of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 3P5, Canada; <email>edechia@myumanitoba.ca</email></aff><aff id="af3-microorganisms-08-01201"><label>3</label>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, MB R3E 3M4, Canada</aff><author-notes><corresp id="c1-microorganisms-08-01201"><label>*</label>Correspondence: <email>ikeogun@myumanitoba.ca</email> (N.M.I.); <email>jude.uzonna@umanitoba.ca</email> (J.E.U.); Tel.: +1-204-977-5659 (J.E.U.)</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2020</year></pub-date><volume>8</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">364399</issue-id><elocation-id>1201</elocation-id><history><date date-type="received"><day>15</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>04</day><month>8</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>08</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-11 07:25:15.050"><day>11</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="microorganisms-08-01201.pdf"/><abstract><p>Parasitic diseases still constitute a major global health problem affecting billions of people around the world. These diseases are capable of becoming chronic and result in high morbidity and mortality. Worldwide, millions of people die each year from parasitic diseases, with the bulk of those deaths resulting from parasitic protozoan infections. Leishmaniasis, which is a disease caused by over 20 species of the protozoan parasite belonging to the genus <italic toggle="yes">Leishmania</italic>, is an important neglected disease. According to the World Health Organization (WHO), an estimated 12 million people are currently infected in about 98 countries and about 2 million new cases occur yearly, resulting in about 50,000 deaths each year. Current treatment methods for leishmaniasis are not very effective and often have significant side effects. In this review, we discussed host immunity to leishmaniasis, various treatment options currently being utilized, and the progress of both immunotherapy and vaccine development strategies used so far in leishmaniasis. We concluded with insights into what the future holds toward the fight against this debilitating parasitic disease.</p></abstract><kwd-group><kwd><italic toggle="yes">Leishmania</italic> infection</kwd><kwd>immunotherapy</kwd><kwd>cytokines</kwd><kwd>myeloid cells</kwd><kwd>T cells</kwd><kwd>vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-microorganisms-08-01201"><title>1. Introduction</title><p>Leishmaniasis, a parasitic disease that affects humans and animals, is mainly transmitted from one host to another through the bite of an infected phlebotomine sand fly vector. Over 20 species of <italic toggle="yes">Leishmania</italic> have been reported to cause various forms of leishmaniasis, including cutaneous, mucocutaneous, and visceral forms [<xref rid="B1-microorganisms-08-01201" ref-type="bibr">1</xref>,<xref rid="B2-microorganisms-08-01201" ref-type="bibr">2</xref>]. Visceral leishmaniasis (VL), also known as kala-azar, is caused by <italic toggle="yes">L. donovani</italic>, and <italic toggle="yes">L. infantum</italic> [<xref rid="B3-microorganisms-08-01201" ref-type="bibr">3</xref>,<xref rid="B4-microorganisms-08-01201" ref-type="bibr">4</xref>]. Fever, anorexia, anemia, and weight loss accompanied by an enlarged liver and spleen are the major clinical signs and symptoms of VL, and the disease can be fatal if left untreated [<xref rid="B2-microorganisms-08-01201" ref-type="bibr">2</xref>]. Mucocutaneous leishmaniasis (MCL), on the other hand, is caused by <italic toggle="yes">L. panamensis</italic>, <italic toggle="yes">L. braziliensis,</italic> and <italic toggle="yes">L. guyanensis</italic>, and is associated with a partial or complete damage of the oral, nasal, and tracheal mucosa, as well as ulcerated lesions on the skin, resulting in serious disability and lifelong scar formation [<xref rid="B2-microorganisms-08-01201" ref-type="bibr">2</xref>,<xref rid="B5-microorganisms-08-01201" ref-type="bibr">5</xref>]. Cutaneous leishmaniasis (CL), widely regarded as the most common form of the disease, is caused by <italic toggle="yes">L. major, L. mexicana</italic>, and <italic toggle="yes">L. tropica</italic>. This form of the disease is characterized by development of skin lesions (papules and ulcers) at the site of the sand fly bite, and the disease is usually self-resolving [<xref rid="B2-microorganisms-08-01201" ref-type="bibr">2</xref>]. Like the mucocutaneous form, skin lesions caused by cutaneous leishmaniasis can leave the individual with lifelong scars and potentially lead to disability [<xref rid="B6-microorganisms-08-01201" ref-type="bibr">6</xref>,<xref rid="B7-microorganisms-08-01201" ref-type="bibr">7</xref>].</p><p>Members of the <italic toggle="yes">Leishmania</italic> species exist as promastigotes (extracellular, flagellated, and spindle-shaped organisms) in the sand fly vector. The promastigotes develop near the endothelial cells of the sand fly&#8217;s mid-gut [<xref rid="B8-microorganisms-08-01201" ref-type="bibr">8</xref>,<xref rid="B9-microorganisms-08-01201" ref-type="bibr">9</xref>]. Because sand flies are hematophagous, they inject their parasite-containing saliva into the host during a blood meal [<xref rid="B10-microorganisms-08-01201" ref-type="bibr">10</xref>,<xref rid="B11-microorganisms-08-01201" ref-type="bibr">11</xref>]. The injected promastigotes are engulfed by dendritic cells (DCs) or epidermal macrophages which serve as antigen presenting cells (APCs). Within the phagolysosome of these APCs, the promastigotes transform into amastigotes (which are round, immotile, and non-flagellated). Amastigotes have the capacity to survive within macrophages, proliferate by binary fission, and eventually rupture the infected cells. The parasites that are released from infected macrophages are also taken up by other macrophages to perpetuate infection in the host. Following a blood meal on an infected host, the sand fly ingests the released amastigotes, and these transform back into flagellated spindle-shaped promastigotes within the fly midgut, thus completing the parasite&#8217;s life cycle [<xref rid="B10-microorganisms-08-01201" ref-type="bibr">10</xref>,<xref rid="B11-microorganisms-08-01201" ref-type="bibr">11</xref>,<xref rid="B12-microorganisms-08-01201" ref-type="bibr">12</xref>].</p><p>In addition to millions of new cases and thousands of deaths attributed to leishmaniasis every year, approximately 300 million people also reside in areas where the disease is endemic [<xref rid="B2-microorganisms-08-01201" ref-type="bibr">2</xref>]. In addition, the disease (particularly cutaneous leishmaniasis) has been reported in tourists who visited endemic countries and Canadian and American troops returning from military operations in Afghanistan [<xref rid="B13-microorganisms-08-01201" ref-type="bibr">13</xref>], thereby underscoring the importance of leishmaniasis as a public health problem. Due to the potential global spread and the health and socioeconomic impact of leishmaniasis, certain preventive and treatment measures have been established to curtail this disease. Such measures include the production of drugs for enhanced patient care, improved surveillance, and development of rapid diagnostic techniques [<xref rid="B14-microorganisms-08-01201" ref-type="bibr">14</xref>]. Several treatment modalities currently employed show varying levels of efficacy and preference from region to region and between infected individuals. Pentavalent antimonial may be applied within the lesion site locally, and this has been shown to be effective in individuals suffering from cutaneous leishmaniasis [<xref rid="B15-microorganisms-08-01201" ref-type="bibr">15</xref>,<xref rid="B16-microorganisms-08-01201" ref-type="bibr">16</xref>,<xref rid="B17-microorganisms-08-01201" ref-type="bibr">17</xref>,<xref rid="B18-microorganisms-08-01201" ref-type="bibr">18</xref>]. Amphotericin-B has been employed as a reliable alternative to pentavalent antimonial in resistant VL [<xref rid="B18-microorganisms-08-01201" ref-type="bibr">18</xref>,<xref rid="B19-microorganisms-08-01201" ref-type="bibr">19</xref>]. Ordinarily, Amphotericin B is known to cause acute toxicity, and to avoid this issue, liposomal amphotericin B was developed. Liposomal amphotericin B is better tolerated in host cells and is as efficacious as the original amphotericin B [<xref rid="B15-microorganisms-08-01201" ref-type="bibr">15</xref>,<xref rid="B17-microorganisms-08-01201" ref-type="bibr">17</xref>,<xref rid="B19-microorganisms-08-01201" ref-type="bibr">19</xref>]. In addition to VL, amphotericin B has also been reported to be a viable treatment option for cutaneous leishmaniasis [<xref rid="B20-microorganisms-08-01201" ref-type="bibr">20</xref>]. Another drug, miltefosine, targets the promastigote and amastigote stages of the parasite and is effective against both VL and CL [<xref rid="B21-microorganisms-08-01201" ref-type="bibr">21</xref>,<xref rid="B22-microorganisms-08-01201" ref-type="bibr">22</xref>]. Generally, parenteral administration of antimony is the gold standard and has been very successful as a remedy for cutaneous leishmaniasis in all regions. However, the toxicity and high cost associated with the use of antimonial makes it necessary for newer treatment regimens against leishmaniasis to be developed [<xref rid="B16-microorganisms-08-01201" ref-type="bibr">16</xref>,<xref rid="B23-microorganisms-08-01201" ref-type="bibr">23</xref>]. As such, immunotherapy is being explored as a potential treatment strategy. In addition, there is a growing global effort towards developing a potent multispecies <italic toggle="yes">Leishmania</italic> vaccine [<xref rid="B24-microorganisms-08-01201" ref-type="bibr">24</xref>], and this will largely depend on our ability to fully understand the complex interaction between <italic toggle="yes">Leishmania</italic> and its mammalian host&#8217;s immune system.</p></sec><sec id="sec2-microorganisms-08-01201"><title>2. Immunity to Leishmaniasis</title><p>The successful elimination of <italic toggle="yes">Leishmania</italic> parasites from an infected host relies on the coordination of different key players of the host immune system. As the promastigotes enter into the blood stream following a sand fly bite, until the amastigotes reside within the macrophages, the tussle between the eradication of parasites and establishment of disease will be somewhat decided by the ability of <italic toggle="yes">Leishmania</italic> to modulate and/or evade host immune defenses. The components of host defense that are necessary for parasite clearance include elements of the innate and adaptive immune systems.</p><sec id="sec2dot1-microorganisms-08-01201"><title>2.1. The Innate Immune Response in Leishmaniasis</title><sec id="sec2dot1dot1-microorganisms-08-01201"><title>2.1.1. Neutrophils</title><p>In leishmaniasis, the innate immune response is mainly mediated by macrophages, dendritic cells, natural killer cells, and neutrophils. These cells interact to determine susceptibility/resistance to the infection by modulating the ensuing adaptive immune response [<xref rid="B25-microorganisms-08-01201" ref-type="bibr">25</xref>,<xref rid="B26-microorganisms-08-01201" ref-type="bibr">26</xref>,<xref rid="B27-microorganisms-08-01201" ref-type="bibr">27</xref>]. There are divergent views on the role of neutrophils in the host immune response to leishmaniasis. At the early stages of infection, neutrophils migrate through the vasculature and are recruited to the site of infection, where they phagocytose parasites and eliminate them through a variety of mechanisms [<xref rid="B28-microorganisms-08-01201" ref-type="bibr">28</xref>,<xref rid="B29-microorganisms-08-01201" ref-type="bibr">29</xref>]. One such mechanism involves the use of neutrophil extracellular traps (NETs) [<xref rid="B28-microorganisms-08-01201" ref-type="bibr">28</xref>,<xref rid="B30-microorganisms-08-01201" ref-type="bibr">30</xref>]. The antileishmanial potency of NETs varies depending on the species of <italic toggle="yes">Leishmania</italic> involved. For instance, although NETs are effective against <italic toggle="yes">L. amazonensis</italic>, they are ineffective against <italic toggle="yes">L. infantum</italic>, <italic toggle="yes">L. donovani</italic>, and <italic toggle="yes">L. mexicana</italic> [<xref rid="B28-microorganisms-08-01201" ref-type="bibr">28</xref>]. In another study, Novais et al. showed that depletion of neutrophils in vivo after <italic toggle="yes">L. braziliensis</italic> infection resulted in a remarkable increase in parasite load in infected BALB/c mice, suggesting that they contribute to resistance [<xref rid="B14-microorganisms-08-01201" ref-type="bibr">14</xref>]. Nitric oxide (NO) is regarded as the major anti-<italic toggle="yes">Leishmania</italic> effector molecule in infected cells [<xref rid="B31-microorganisms-08-01201" ref-type="bibr">31</xref>,<xref rid="B32-microorganisms-08-01201" ref-type="bibr">32</xref>,<xref rid="B33-microorganisms-08-01201" ref-type="bibr">33</xref>,<xref rid="B34-microorganisms-08-01201" ref-type="bibr">34</xref>]. A study conducted by Charmoy et al. showed that neutrophils isolated from <italic toggle="yes">Leishmania</italic>-resistant C57BL/6 mice harbored significantly fewer parasites than those isolated from <italic toggle="yes">Leishmania</italic>-susceptible BALB/c mice. Furthermore, neutrophils from C57BL/6 were shown to significantly secrete more NO than those from the susceptible BALB/c mice in response to IFN-&#947; stimulation <italic toggle="yes">in vitro</italic>. This observation from Charmoy et al. suggests that neutrophils may contribute to anti-<italic toggle="yes">Leishmania</italic> immunity by utilizing NO-dependent mechanisms to eliminate <italic toggle="yes">Leishmania</italic> parasites [<xref rid="B35-microorganisms-08-01201" ref-type="bibr">35</xref>]. In contrast, the pro-<italic toggle="yes">Leishmania</italic> activity of neutrophils was demonstrated by Peters et al., who showed that depletion of neutrophils in <italic toggle="yes">L. major</italic>-infected C57BL/6 mice resulted in decreased parasite load and diminished the progression of disease [<xref rid="B36-microorganisms-08-01201" ref-type="bibr">36</xref>]. Neutrophils have also been shown to enhance the infection of macrophages by upregulating a macrophage chemokine, MIP-1&#946; (CCL4) [<xref rid="B37-microorganisms-08-01201" ref-type="bibr">37</xref>]. Neutrophils are rapidly mobilized to the site of <italic toggle="yes">Leishmania</italic> infection via <italic toggle="yes">Leishmania</italic> chemotactic factor (LCF), a selective neutrophil chemokine [<xref rid="B38-microorganisms-08-01201" ref-type="bibr">38</xref>]. These neutrophils are able to phagocytose <italic toggle="yes">Leishmania</italic> and secrete Interleukin 8 (IL-8), which, in turn, increases the number of neutrophils migrating to the site of infection [<xref rid="B39-microorganisms-08-01201" ref-type="bibr">39</xref>]. The infected neutrophils become apoptotic and secrete macrophage chemokines such as MIP-1&#946; (CCL4), which leads to the chemotaxis of macrophages to the site of infection. At the site of infection, these macrophages phagocytose the infected apoptotic neutrophils. The phagocytosed <italic toggle="yes">Leishmania</italic> parasites (from the apoptotic neutrophils) are able to survive and multiply within macrophages, further establishing the disease [<xref rid="B39-microorganisms-08-01201" ref-type="bibr">39</xref>]. This observation leads to neutrophils being referred to as &#8220;Trojan horses.&#8221; The participation of neutrophils in leishmaniasis has been shown to be modulated to some extent by the mode of <italic toggle="yes">Leishmania</italic> infection. Peter et al. observed massive, sustained, and localized neutrophil recruitment to the site of a sand fly bite compared to a needle injection in the dermis [<xref rid="B40-microorganisms-08-01201" ref-type="bibr">40</xref>]. Taken together, these studies indicate that the role of neutrophils in host immune response to <italic toggle="yes">Leishmania</italic> infection may depend on the parasite species, mouse model used, and the mode of infection.</p></sec><sec id="sec2dot1dot2-microorganisms-08-01201"><title>2.1.2. Macrophages</title><p>Macrophages are also present at the site of <italic toggle="yes">Leishmania</italic> infection. Although neutrophils and macrophages are both infected by <italic toggle="yes">Leishmania</italic> parasites, macrophages serve as the major infected cells that perpetuate the infection in the host because they live longer than neutrophils [<xref rid="B31-microorganisms-08-01201" ref-type="bibr">31</xref>,<xref rid="B41-microorganisms-08-01201" ref-type="bibr">41</xref>,<xref rid="B42-microorganisms-08-01201" ref-type="bibr">42</xref>].</p><p>As well, <italic toggle="yes">Leishmania</italic> parasites are able to promote their survival in macrophages. One mechanism by which they do so is by suppressing Interleukin 12 (IL-12) production in infected macrophages [<xref rid="B9-microorganisms-08-01201" ref-type="bibr">9</xref>,<xref rid="B43-microorganisms-08-01201" ref-type="bibr">43</xref>]. IL-12 is a key cytokine that induces the T-helper 1 (Th1) response which is essential for parasite elimination in infected macrophages [<xref rid="B44-microorganisms-08-01201" ref-type="bibr">44</xref>,<xref rid="B45-microorganisms-08-01201" ref-type="bibr">45</xref>,<xref rid="B46-microorganisms-08-01201" ref-type="bibr">46</xref>]. It has been shown that the outcome of <italic toggle="yes">Leishmania</italic> infection in macrophages depends on their activation status <bold>[<xref rid="B42-microorganisms-08-01201" ref-type="bibr">42</xref>,<xref rid="B47-microorganisms-08-01201" ref-type="bibr">47</xref>,<xref rid="B48-microorganisms-08-01201" ref-type="bibr">48</xref>,<xref rid="B49-microorganisms-08-01201" ref-type="bibr">49</xref>]</bold>. Classical activation of macrophages is mediated by Interferon gamma (IFN-&#947;), an effector cytokine secreted by CD4<sup>+</sup> T helper type 1 (Th1) cells, CD8<sup>+</sup> T cells, and natural killer (NK) cells [<xref rid="B50-microorganisms-08-01201" ref-type="bibr">50</xref>]<bold>.</bold> Upon IFN-&#947; stimulation, macrophages produce inducible nitric oxide synthase (iNOS), which converts L-arginine to nitric oxide (NO), a critical effector molecule for killing of intracellular amastigotes [<xref rid="B50-microorganisms-08-01201" ref-type="bibr">50</xref>]. iNOS production is dependent on NF-&#954;B transcription [<xref rid="B51-microorganisms-08-01201" ref-type="bibr">51</xref>] and is important in facilitating the clearance of parasites. Gregory et al. reported that <italic toggle="yes">Leishmania</italic> parasites inhibit the production of NO by suppressing the production and/or activation of iNOS via <italic toggle="yes">Leishmania</italic> protease (gp63)-mediated cleavage of p65 subunit of NF- &#954;B [<xref rid="B51-microorganisms-08-01201" ref-type="bibr">51</xref>]. Also, <italic toggle="yes">Leishmania</italic> parasites inhibit NO production by increasing the expression of arginase which competitively cleaves L-arginine into ornithine [<xref rid="B52-microorganisms-08-01201" ref-type="bibr">52</xref>]. Ornithine favors the proliferation of <italic toggle="yes">Leishmania</italic> parasites in macrophages [<xref rid="B53-microorganisms-08-01201" ref-type="bibr">53</xref>]. Indeed, Wei et al. showed that the normally resistant (C57BL/6) mice that lost the capacity to synthesize iNOS became susceptible to <italic toggle="yes">L. major</italic> infection, although they maintained a strong IFN-&#947; type response [<xref rid="B54-microorganisms-08-01201" ref-type="bibr">54</xref>]. An iNOS inhibitor, N(G)-monomethyl-L-arginine, suppressed IFN-&#947; mediated parasite clearance in both mice and human macrophages in vitro [<xref rid="B55-microorganisms-08-01201" ref-type="bibr">55</xref>]. Furthermore, the administration of another iNOS inhibitor, L-N6-iminoethyl-lysine, in C57BL/6 mice, which healed their primary <italic toggle="yes">L. major</italic> infection, resulted in disease recrudescence and a 10-fold increase in parasite burden at both the draining lymph node and cutaneous site of infection. This observation suggests that continuous iNOS expression is important for primary resistance to <italic toggle="yes">L. major</italic> infection, as well as for the maintenance of infection-induced immunity in healed mice [<xref rid="B56-microorganisms-08-01201" ref-type="bibr">56</xref>].</p></sec><sec id="sec2dot1dot3-microorganisms-08-01201"><title>2.1.3. Monocytes</title><p>Monocytes are also recruited to the site of <italic toggle="yes">Leishmania</italic> infection via chemokines (such as MIP-1&#946; and CCL3), cytokines (such as Interleukin 8 and Tumor necrosis factor- alpha), and complement proteins, notably C5a, the breakdown product of C5 [<xref rid="B57-microorganisms-08-01201" ref-type="bibr">57</xref>]. Romano et al. reported that monocytes serve as the main cell types where parasite replication occurs in vivo [<xref rid="B58-microorganisms-08-01201" ref-type="bibr">58</xref>]. They further reported that early on during primary <italic toggle="yes">L. major</italic> infection, Major histocompatibility complex (MHC) II maturation of inflammatory monocytes is disrupted, unlike in secondary sites of infection. They showed that monocytes from secondary sites of infection expressed significantly higher CD86 than those from primary sites of infection. This suggests that infected monocytes at secondary sites of infection undergo extensive maturation compared to those at the primary sites of infection. This finding suggests that the in vitro infection of monocytes (as opposed to the conventional macrophage models) may be a more suitable model to study the role of <italic toggle="yes">Leishmania</italic> parasites as modulators of phagocyte maturation. This is because, in conventional macrophage models, the ability of parasites to suppress the maturation of phagocytes are assessed in already mature cells (macrophages) [<xref rid="B58-microorganisms-08-01201" ref-type="bibr">58</xref>]. Furthermore, Romano et al. showed that following secondary <italic toggle="yes">L. major</italic> challenge, CCR2<sup>+</sup> monocytes, which respond to CXCL10 (a chemokine produced by inflammatory cells like neutrophils in response to IFN-&#947;), are the major source of iNOS<sup>+</sup> cells and are essential to the clearance of intracellular <italic toggle="yes">L. major</italic> parasites. The authors also suggested that neutrophils rely on CCR2<sup>+</sup> monocytes for parasite clearance, as they observed that neutrophils from CCR2 depleted mice (mice which lacked monocytes) as opposed to those from CCR2 competent mice showed no evidence of leishmanicidal activity, but instead served as a safe haven for the parasites in <italic toggle="yes">L. major-</italic>infected CCR2-depleted mice.</p></sec><sec id="sec2dot1dot4-microorganisms-08-01201"><title>2.1.4. Dendritic Cells</title><p>Dendritic cells (DCs) are also infected by <italic toggle="yes">Leishmania</italic> and are known to be critical for antigen presentation and induction and differentiation of na&#239;ve CD4<sup>+</sup> T cells into effector Th1 cells [<xref rid="B59-microorganisms-08-01201" ref-type="bibr">59</xref>,<xref rid="B60-microorganisms-08-01201" ref-type="bibr">60</xref>,<xref rid="B61-microorganisms-08-01201" ref-type="bibr">61</xref>,<xref rid="B62-microorganisms-08-01201" ref-type="bibr">62</xref>,<xref rid="B63-microorganisms-08-01201" ref-type="bibr">63</xref>]. These effector Th1 cells are necessary for resistance to <italic toggle="yes">Leishmania</italic> infection [<xref rid="B64-microorganisms-08-01201" ref-type="bibr">64</xref>,<xref rid="B65-microorganisms-08-01201" ref-type="bibr">65</xref>,<xref rid="B66-microorganisms-08-01201" ref-type="bibr">66</xref>,<xref rid="B67-microorganisms-08-01201" ref-type="bibr">67</xref>]. As <italic toggle="yes">Leishmania</italic> infection progresses, DCs serve as major producers of IL-12, which is needed to prime na&#239;ve CD4<sup>+</sup> T cells to differentiate into protective Th1 cells [<xref rid="B59-microorganisms-08-01201" ref-type="bibr">59</xref>,<xref rid="B60-microorganisms-08-01201" ref-type="bibr">60</xref>,<xref rid="B61-microorganisms-08-01201" ref-type="bibr">61</xref>,<xref rid="B62-microorganisms-08-01201" ref-type="bibr">62</xref>,<xref rid="B63-microorganisms-08-01201" ref-type="bibr">63</xref>,<xref rid="B68-microorganisms-08-01201" ref-type="bibr">68</xref>]. DCs also express costimulatory molecules such as CD40, CD80, and CD86 [<xref rid="B69-microorganisms-08-01201" ref-type="bibr">69</xref>]. These costimulatory molecules have been reported to contribute to host immunity to leishmaniasis. Okwor et al. showed that antibody-mediated blockade of CD40-CD40L interaction in <italic toggle="yes">L. major</italic>-infected mice resulted in decreased production of IL-12 and IFN-&#947; and increased parasite burden [<xref rid="B70-microorganisms-08-01201" ref-type="bibr">70</xref>]. Also, Kamanaka et al. reported that CD4- deficient C57BL/6 mice were more susceptible to <italic toggle="yes">L. major</italic> infection compared to their WT counterparts. They observed that CD40 deficiency in <italic toggle="yes">L. major</italic>-infected C57BL/6 mice tilted the Th1/Th2 balance in the favor of pro-<italic toggle="yes">Leishmania</italic> Th2 as opposed to anti-<italic toggle="yes">Leishmania</italic> Th1. This was accompanied by decreased IL-12p40 and IFN-&#947; response following infection [<xref rid="B71-microorganisms-08-01201" ref-type="bibr">71</xref>]. In the same study, it was shown that deficiency of CD40 ligand (CD40L, normally expressed on T cell) in <italic toggle="yes">L. major</italic>-infected C57BL/6 mice resulted in a decreased Th1 immune response against <italic toggle="yes">L. major</italic> infection, leading to the development of ulcerating lesions. This increased disease severity in CD40L deficient mice was associated with inability of their Th1 cells to induce IL-12 production in macrophages. The administration of recombinant CD40L to infected CD40L deficient mice resulted in decreased lesion size and parasite burden [<xref rid="B71-microorganisms-08-01201" ref-type="bibr">71</xref>]. Hathcock et al. reported that Th2 response in BALB/c mice is dependent on CD86 expression [<xref rid="B72-microorganisms-08-01201" ref-type="bibr">72</xref>]. Interestingly, they also showed that the early Th1 immune response that confers protection to <italic toggle="yes">L. major</italic> in C57BL/6 relies on CD86 signaling, suggesting that the role of CD86 in leishmaniasis may be dependent on the genetic background of the mice [<xref rid="B72-microorganisms-08-01201" ref-type="bibr">72</xref>].</p></sec><sec id="sec2dot1dot5-microorganisms-08-01201"><title>2.1.5. Natural Killer (NK) Cells</title><p>Another group of innate immune cells that play a role in immunity to leishmaniasis are NK cells [<xref rid="B73-microorganisms-08-01201" ref-type="bibr">73</xref>,<xref rid="B74-microorganisms-08-01201" ref-type="bibr">74</xref>,<xref rid="B75-microorganisms-08-01201" ref-type="bibr">75</xref>]. Mouse infection studies showed that early (seven days post infection) depletion of NK cells decreased IFN-&#947; production and led to significant increase in parasite burden [<xref rid="B76-microorganisms-08-01201" ref-type="bibr">76</xref>]. It was also reported that HeN mice were resistant to <italic toggle="yes">L. major</italic> infection, and this was attributed to NK cell-mediated early IFN-&#947; production [<xref rid="B77-microorganisms-08-01201" ref-type="bibr">77</xref>]. In contrast, the enhanced susceptibility to leishmaniasis observed in BALB/c mice was associated with diminished NK cell activity [<xref rid="B73-microorganisms-08-01201" ref-type="bibr">73</xref>]. Collectively, these studies suggest that NK cells contribute to host protection during <italic toggle="yes">Leishmania</italic> infection.</p></sec></sec><sec id="sec2dot2-microorganisms-08-01201"><title>2.2. The Adaptive Immune Response in Leishmaniasis</title><p>The adaptive immune system is composed of T and B cells that mediate cell-mediated and humoral immunity, respectively. Unlike innate immunity, adaptive immunity is specific, highly specialized, and possesses immunologic memory. T cells are the major components of the host immune system that are responsible for cell-mediated immunity. Cell-mediated immunity has been shown to play a critical protective role against <italic toggle="yes">Leishmania</italic> parasites. The protective role of T cells in leishmaniasis is well established, and this was evidenced by the observation that mice that are ordinarily resistant to <italic toggle="yes">Leishmania</italic> infection became highly susceptible when their T cell response was disrupted. Furthermore, the adoptive transfer of functional T cells to these susceptible mice (with a disrupted T cell response) restored resistance to <italic toggle="yes">Leishmania</italic> infection [<xref rid="B78-microorganisms-08-01201" ref-type="bibr">78</xref>].</p><sec id="sec2dot2dot1-microorganisms-08-01201"><title>2.2.1. CD4<sup>+</sup> T Cells</title><p>Various subsets of CD4<sup>+</sup> T cells play different roles in leishmaniasis. IFN-&#947;-producing CD4<sup>+</sup> Th1 cells are the major cells involved in parasite control in resistant mice. IFN-&#947;, which is generally regarded as the &#8216;signature&#8217; Th1 cytokine, activates macrophages into an M1 phenotype, resulting in nitric oxide production and enhanced elimination of parasites resident in these macrophages [<xref rid="B53-microorganisms-08-01201" ref-type="bibr">53</xref>,<xref rid="B64-microorganisms-08-01201" ref-type="bibr">64</xref>,<xref rid="B65-microorganisms-08-01201" ref-type="bibr">65</xref>,<xref rid="B66-microorganisms-08-01201" ref-type="bibr">66</xref>,<xref rid="B67-microorganisms-08-01201" ref-type="bibr">67</xref>]. The C57BL/6 mice are resistant to <italic toggle="yes">L. major</italic> because they mount a strong Th1 immune response against <italic toggle="yes">Leishmania</italic> parasites. In contrast, BALB/c mice are highly susceptible due to their relatively weaker Th1 but stronger Th2 responses [<xref rid="B12-microorganisms-08-01201" ref-type="bibr">12</xref>]. Th2 cells contribute to susceptibility of BALB/c mice to leishmaniasis by producing cytokines (such as IL-4 and IL-10) that deactivate infected macrophages and suppress the iNOS pathway, which is important for eliminating intracellular <italic toggle="yes">Leishmania</italic> parasites [<xref rid="B12-microorganisms-08-01201" ref-type="bibr">12</xref>]. Interestingly, the immunosuppressive effect of Th2 cells in BALB/c mice was reversed following depletion of neutrophils, and this was shown to be related to the downregulation of primary IL-4 response, thereby conferring more protection to the mice [<xref rid="B79-microorganisms-08-01201" ref-type="bibr">79</xref>].</p><p>The role T-helper 17 (Th17) cells, play in immunity to <italic toggle="yes">Leishmania</italic> infection depends on the parasite species. This is because some studies have shown that Th17 cells promote susceptibility to <italic toggle="yes">L. major</italic> infection [<xref rid="B80-microorganisms-08-01201" ref-type="bibr">80</xref>] but contribute to resistance to <italic toggle="yes">L. infantum</italic> [<xref rid="B81-microorganisms-08-01201" ref-type="bibr">81</xref>] and <italic toggle="yes">L. donovani</italic> [<xref rid="B82-microorganisms-08-01201" ref-type="bibr">82</xref>] infections. Gonzalez-Lombana et al. reported that Th17 cells enhanced host susceptibility to <italic toggle="yes">L. major</italic> infection by promoting excessive immune response [<xref rid="B80-microorganisms-08-01201" ref-type="bibr">80</xref>]. On the other hand, Nascimento et al. identified IL-17A as a critical host molecule in immunity against <italic toggle="yes">L. infantum</italic>. In this study, IL-17R deficient C57BL/6 mice displayed increased susceptibility to <italic toggle="yes">L. infantum</italic> infection, as evidenced by higher parasite burden when compared to their WT counterpart mice. The increased parasite burden in IL-17R deficient C57BL/6 mice was attributed to the significant increase in IL-10-secreting regulatory T cells, coupled with a reduction in the number of CD4<sup>+</sup> Th1 cells [<xref rid="B81-microorganisms-08-01201" ref-type="bibr">81</xref>]. In another study, Th17 cells were also reported to be associated with resistance to <italic toggle="yes">L. donovani</italic> infection in mice due to their ability to induce chemokine secretion, which attracts neutrophils and Th1 cells to the infected sites [<xref rid="B82-microorganisms-08-01201" ref-type="bibr">82</xref>].</p><p>Naturally occurring regulatory T cells (Tregs) are also found at the infected sites in cutaneous leishmaniasis, where they limit the function of effector CD4<sup>+</sup> T cells through both IL-10 independent or dependent mechanisms, thus promoting long-term parasite persistence [<xref rid="B83-microorganisms-08-01201" ref-type="bibr">83</xref>]. This parasite persistence is beneficial to the host because it enhances the establishment of durable immunity against the parasite [<xref rid="B84-microorganisms-08-01201" ref-type="bibr">84</xref>]. This model also illustrates the importance of a host-parasite equilibrium that appears to benefit both the host and the parasite [<xref rid="B85-microorganisms-08-01201" ref-type="bibr">85</xref>]. Persistence ensures the maintenance of effector memory cells that mediate infection-induced immunity in the host, as well a stable source or reservoir of parasites for transmission from one host to the other by the sand fly. In line with this, the development of lesions in mice infected with <italic toggle="yes">L. major</italic> has been associated with a high number of IL-10-secreting Tregs present at the infected site [<xref rid="B86-microorganisms-08-01201" ref-type="bibr">86</xref>]. As well, the adoptive transfer of Tregs isolated from acutely infected mice to chronically infected mice was shown to lead to disease recurrence and the disruption of effector memory T cell response [<xref rid="B87-microorganisms-08-01201" ref-type="bibr">87</xref>].</p></sec><sec id="sec2dot2dot2-microorganisms-08-01201"><title>2.2.2. CD8<sup>+</sup> T Cells</title><p>Although CD4<sup>+</sup> T cells are the key cells responsible for anti-<italic toggle="yes">Leishmania</italic> immunity, CD8<sup>+</sup> T cells that are specific to <italic toggle="yes">Leishmania</italic> antigens have also been identified [<xref rid="B88-microorganisms-08-01201" ref-type="bibr">88</xref>]. The role of CD8<sup>+</sup> T cells in regulating host immune response in leishmaniasis is controversial. In one study, mice deficient in CD8<sup>+</sup> T cells or class I MHC (which is necessary for CD8<sup>+</sup> T cell development and activation) were able to effectively control primary <italic toggle="yes">L. major</italic> infection [<xref rid="B89-microorganisms-08-01201" ref-type="bibr">89</xref>]. However, another study demonstrated that CD8<sup>+</sup> T cells are crucial for resistance during low-dose parasite infection and for mounting an effective secondary immune response [<xref rid="B88-microorganisms-08-01201" ref-type="bibr">88</xref>]. Uzonna et al. studied the mechanism of CD8<sup>+</sup> T cell-mediated protection during low-dose infection [<xref rid="B90-microorganisms-08-01201" ref-type="bibr">90</xref>]. Their study demonstrated that a transient early Th2 response was induced in C57BL/6 mice following low-dose <italic toggle="yes">L. major</italic> infection. However, this transient Th2 response was suppressed by IFN-&#947; produced by CD8<sup>+</sup> T cells, leading to sustained Th1 response and the development of protective immunity [<xref rid="B90-microorganisms-08-01201" ref-type="bibr">90</xref>]. In line with this, infection of CD8<sup>+</sup> T cell-deficient C57BL/6 mice with low parasite dose resulted in persistent Th2 response and susceptibility, evidenced by increased cutaneous lesion and high parasite burden [<xref rid="B90-microorganisms-08-01201" ref-type="bibr">90</xref>]. Okwor et al. also showed that although CD8<sup>+</sup> T cells are selectively activated and contribute to optimal primary immunity after low-dose infection, they are dispensable during secondary immunity [<xref rid="B91-microorganisms-08-01201" ref-type="bibr">91</xref>].</p><p>Whereas the role of CD8<sup>+</sup> T cells in primary immunity is equivocal, their role in vaccine-induced immunity is unequivocal. Mendez et al. showed that CD8<sup>+</sup> T cells are important for vaccine-induced immunity in <italic toggle="yes">L. major</italic> infection [<xref rid="B92-microorganisms-08-01201" ref-type="bibr">92</xref>]. In this study, they reported that depletion of CD8<sup>+</sup> T cells in vivo before vaccination with DNA expressing LACK (<italic toggle="yes">Leishmania</italic> homologue of receptors for activated C kinase), TSA (<italic toggle="yes">L. major</italic> recombinant protein homologue to eukaryotic thiol-specific-antioxidant protein), and LmSTI1 (<italic toggle="yes">L. major</italic> recombinant protein homologue to eukaryotic stress-inducible protein) compromised the ability of the vaccine to confer full protection following <italic toggle="yes">L. major</italic> challenge [<xref rid="B92-microorganisms-08-01201" ref-type="bibr">92</xref>]. Although there was an observed delay in lesion development in vaccinated C57BL/6 mice treated with anti-CD8 antibody, the lesions progressed to a size comparable to unvaccinated controls [<xref rid="B92-microorganisms-08-01201" ref-type="bibr">92</xref>]. In addition, CD8<sup>+</sup> T cells were also shown to be important in vaccine studies with BALB/c mice. Gurunathan et al. reported that LACK DNA vaccination in conjunction with CD8<sup>+</sup> T cell depletion in BALB/c mice failed to confer protection to the vaccinated BALB/c mice following <italic toggle="yes">L. major</italic> challenge [<xref rid="B93-microorganisms-08-01201" ref-type="bibr">93</xref>]. When LACK DNA vaccinated mice were treated with anti-CD8, the frequency of IFN-&#947; producing CD4<sup>+</sup> T cells were diminished both at 2 and 12 weeks post vaccination, suggesting that CD8<sup>+</sup> T cells are critical for maintaining Th1 immune response in vaccinated mice [<xref rid="B93-microorganisms-08-01201" ref-type="bibr">93</xref>]. Collectively, these observations indicate that CD8<sup>+</sup> T cells play a critical role in vaccine-induced immunity in leishmaniasis.</p></sec><sec id="sec2dot2dot3-microorganisms-08-01201"><title>2.2.3. B Cells</title><p>Generally, B cells are not regarded as major contributors to protective immunity against leishmaniasis. This is because <italic toggle="yes">Leishmania</italic> are intracellular parasites and reside in the vacuole of macrophages, and as such, may not be easily accessed by antibodies [<xref rid="B94-microorganisms-08-01201" ref-type="bibr">94</xref>]. To demonstrate that B cells are not protective in leishmaniasis, BALB/c mice that were sub lethally irradiated became resistant to leishmaniasis when the donor cells were CD4<sup>+</sup> T cells but not when B cells were transferred [<xref rid="B95-microorganisms-08-01201" ref-type="bibr">95</xref>]. Furthermore, the transfer of serum from healed mice did not confer protection [<xref rid="B96-microorganisms-08-01201" ref-type="bibr">96</xref>]. However, there is some evidence to suggest that B cells may play a role in protective immune response to <italic toggle="yes">Leishmania</italic> infection. Woelbing et al. reported that IgG antibodies secreted by activated B cells in <italic toggle="yes">L. major</italic>-infected C57BL/6 mice increased antigen uptake capacity by dendritic cells via Fc gamma 3 receptor (Fc&#947;R III) [<xref rid="B97-microorganisms-08-01201" ref-type="bibr">97</xref>]. This increased antigen uptake was associated with increased antigen presentation by dendritic cells, which resulted in an increased Th1 response [<xref rid="B97-microorganisms-08-01201" ref-type="bibr">97</xref>]. In line with this, <italic toggle="yes">L. major-</italic>infected B cell deficient C57BL/6 mice displayed significant reduction in IFN-&#947; secretion and increased lesion and parasite burden, and this was reversed upon infection with IgG-opsonized parasites [<xref rid="B97-microorganisms-08-01201" ref-type="bibr">97</xref>].</p></sec></sec></sec><sec id="sec3-microorganisms-08-01201"><title>3. Advances in Vaccination against Leishmaniasis</title><p>Recovery from natural infection with most species of <italic toggle="yes">Leishmania</italic> that cause cutaneous leishmaniasis results in protection to secondary infection. This infection-induced immunity suggests that vaccination may serve as a viable option to prevent cutaneous leishmaniasis in both animals and man. Consequently, studies have been designed to determine the most effective vaccination approach against the different forms of leishmaniasis.</p><p>Whereas human vaccination studies have been disappointing, several animal vaccines appear to be effective. Vaccines, such as CaniLeish<sup>&#174;</sup> and Leishmune<sup>&#174;</sup> have shown remarkable success in the prevention of canine leishmaniasis. These vaccines, licensed for veterinary use, have been shown to confer protection in dogs and therefore prevent zoonotic transmission of leishmaniasis to humans [<xref rid="B98-microorganisms-08-01201" ref-type="bibr">98</xref>]. The administration of Leishmune, a fucose-mannose ligand (FML)-based vaccine, in combination with saponin (as an adjuvant), was reported to protect 92&#8211;97% of vaccinated dogs against <italic toggle="yes">L. infantum</italic> infection [<xref rid="B98-microorganisms-08-01201" ref-type="bibr">98</xref>,<xref rid="B99-microorganisms-08-01201" ref-type="bibr">99</xref>]. Moreno et al. assessed the efficiency of LiESP/QA-21 vaccine on selected humoral and cellular markers of the canine immune response during the onset of immunity [<xref rid="B100-microorganisms-08-01201" ref-type="bibr">100</xref>]. They showed that vaccinated dogs had significantly increased cell-mediated and humoral immune responses characterized by IFN-&#947; secretion and IgG2 production, respectively. These responses correlated with the induction of iNOS pathway and production of NO derivatives, which have been shown to be an important leishmanicidal mechanism [<xref rid="B100-microorganisms-08-01201" ref-type="bibr">100</xref>]. A recent study with dogs in France and Spain assessed the efficacy of LetiFend<sup>&#174;</sup> (a new vaccine containing recombinant Protein Q) in protecting dogs against <italic toggle="yes">L. infantum</italic> infection. The authors showed that LetiFend<sup>&#174;</sup> can prevent the development of leishmaniasis in six-month-old dogs after natural infection with <italic toggle="yes">Leishmania infantum</italic> [<xref rid="B101-microorganisms-08-01201" ref-type="bibr">101</xref>]. Recently, it was shown that the administration of recombinant ES <italic toggle="yes">La</italic>PSA-38S (rPSA) or its carboxy terminal part (<italic toggle="yes">La</italic>PSA-12S, Cter-rPSA), combined with QA-21 as adjuvant, conferred high levels of protection against <italic toggle="yes">L</italic>. <italic toggle="yes">infantum</italic> in beagles, as evidenced by a significant decrease in parasite burden and an increase in the Th1 immune response [<xref rid="B102-microorganisms-08-01201" ref-type="bibr">102</xref>]</p><p>Cross protection has been reported in vaccine studies in canine leishmaniasis. Roatt et al. observed that the administration of a vaccine comprising of <italic toggle="yes">L. braziliensis</italic> antigens with saponin as an adjuvant (LBSap vaccine) conferred protection to dogs challenged with <italic toggle="yes">L. infantum</italic> mixed with salivary gland extracts. This protection was associated with significant decrease in parasite burden, and increases in IFN-&#947;-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells and total anti-<italic toggle="yes">Leishmania</italic> IgG1 and IgG2 antibody levels [<xref rid="B103-microorganisms-08-01201" ref-type="bibr">103</xref>]. Also, Resende et al. showed that the administration of LbSapSal vaccine (<italic toggle="yes">L</italic>. <italic toggle="yes">braziliensis</italic> antigens, saponin as adjuvant, and <italic toggle="yes">Lutzomyia longipalpis</italic> salivary gland extract) to dogs protected the vaccinated dogs against <italic toggle="yes">L</italic>. <italic toggle="yes">chagasi</italic> challenge, as evidenced by an increase in nitric oxide production and a decreased splenic parasite load [<xref rid="B104-microorganisms-08-01201" ref-type="bibr">104</xref>].</p><p>Sophisticated proteomics and cellular immunology techniques have also been employed in the search for effective <italic toggle="yes">Leishmania</italic> vaccine candidates. Using these technologies, Mou et al. identified a dominant naturally processed peptide (PEPCK<sub>335&#8211;351</sub>) derived from <italic toggle="yes">Leishmania</italic> glycosomal phosphoenolpyruvate carboxykinase (PEPCK) [<xref rid="B105-microorganisms-08-01201" ref-type="bibr">105</xref>]. The peptide and/or its native protein elicited strong CD4<sup>+</sup> T cell responses in infected mice and humans. Similar to PEPCK peptide, rPEPCK, or DNA expressing full-length PEPCK, induced strong and durable cross-species protection in both susceptible and resistant mice [<xref rid="B105-microorganisms-08-01201" ref-type="bibr">105</xref>]. Recently, Lumena et al. showed that mice immunized intradermally with PEPCK were superior in generating skin-resident PEPCK-specific T cells when compared to mice immunized intramuscularly. They further observed that when challenged with <italic toggle="yes">Leishmania major</italic> parasites, intradermal immunization led to significant protection, which was not observed after intramuscular immunization [<xref rid="B106-microorganisms-08-01201" ref-type="bibr">106</xref>].</p><p>Chamakh-Ayari et al. showed that the vaccination of mice with Promastigote Surface Antigen (PSA) from <italic toggle="yes">L. amazonensis</italic> (<italic toggle="yes">La</italic>PSA-38S) conferred protection to the vaccinated mice against virulent infection. Interestingly, <italic toggle="yes">La</italic>PSA-38S also induced IFN-&#947; secretion in human T cells <italic toggle="yes">in vitro</italic>, suggesting that its effect could be translatable to human subjects [<xref rid="B107-microorganisms-08-01201" ref-type="bibr">107</xref>]. Indeed, some human vaccine trials for leishmaniasis have been conducted. In a recent study, Osman et al. described the use of ChAd63-KH, a simian adenovirus DNA-based <italic toggle="yes">L. donovani</italic> antigen vaccine, in human trial [<xref rid="B108-microorganisms-08-01201" ref-type="bibr">108</xref>]. They showed that ChAd63-KH could effectively elicit strong dendritic cell activation and a wide range of CD8<sup>+</sup> T cells response including IFN-&#947; production [<xref rid="B108-microorganisms-08-01201" ref-type="bibr">108</xref>]. This study suggested that ChAd63-KH vaccine could be a potential vaccine candidate to protect humans against <italic toggle="yes">L. donovani</italic> infections [<xref rid="B108-microorganisms-08-01201" ref-type="bibr">108</xref>]<bold>.</bold> Some vaccination strategies against leishmaniasis are summarized in <xref rid="microorganisms-08-01201-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec4-microorganisms-08-01201"><title>4. Advances in Immunotherapy against Leishmaniasis</title><p>Immunotherapy involves the manipulation and/or activation of the immune system in order to boost or redirect the host immune response for effective therapeutic outcome. Immunotherapy for leishmaniasis is based on the principle that nonprotective anti-<italic toggle="yes">Leishmania</italic> immune response could be altered or skewed towards a protective phenotype. This could be achieved by the use of immunomodulatory agents and/or specially formulated <italic toggle="yes">Leishmania</italic> antigens. Thus, immunotherapeutic modalities may involve the use of <italic toggle="yes">Leishmania</italic> antigens, recombinant cytokines and antibodies, or molecules that modulate key immunoregulatory pathways.</p><sec id="sec4dot1-microorganisms-08-01201"><title>4.1. Leishmania Antigens</title><p>A study conducted in the 1990s described the immunotherapy for patients with cutaneous leishmaniasis. Out of 62 patients that received this treatment, 42 were cured following varying rounds of administration of the <italic toggle="yes">Leishmania</italic> cocktail. Although no side effects were reported, treatment with the <italic toggle="yes">Leishmania</italic> cocktail was less effective compared to glucantime (a chemotherapeutic agent) [<xref rid="B110-microorganisms-08-01201" ref-type="bibr">110</xref>]. In a relatively more recent study conducted in 2011, Jamshidi et al. compared the effect of glucantime treatment with immunotherapy consisting of killed <italic toggle="yes">L. major</italic> antigens and <italic toggle="yes">Mycobacterium vaccae</italic> as adjuvant in canine visceral leishmaniasis [<xref rid="B111-microorganisms-08-01201" ref-type="bibr">111</xref>]. They found that immunotherapy alone or in combination with glucantime was more effective against canine visceral leishmaniasis when compared to chemotherapy. Although the study employed a small sample size, their findings add to the growing body of evidence supporting the potential of immunotherapy for treatment of leishmaniasis [<xref rid="B111-microorganisms-08-01201" ref-type="bibr">111</xref>]. A randomized clinical trial to test the efficacy of a recombinant <italic toggle="yes">Leishmania</italic> A2 protein with saponin as adjuvant (LeishTec<sup>&#174;</sup>) was conducted in the US in 2018 on dogs infected with visceral leishmaniasis. In this study, a much larger sample size of 495 dogs was utilized, and LeishTec<sup>&#174;</sup> was reported to reduce the risk of disease progression by 25% and mortality rate by 70% in treated dogs compared to controls [<xref rid="B78-microorganisms-08-01201" ref-type="bibr">78</xref>]. The efficacy of vaccines produced from antigens of <italic toggle="yes">L. braziliensis</italic> in combination with a monophosphoryl lipid A (MPL) adjuvant was investigated in symptomatic dogs with visceral leishmaniasis (caused by <italic toggle="yes">L. infantum</italic>). In this study, the investigators treated 6 dogs with adjuvant alone and 10 dogs with the combination of adjuvant and <italic toggle="yes">L. braziliensis</italic> antigens [<xref rid="B112-microorganisms-08-01201" ref-type="bibr">112</xref>]. The vaccine treatment led to reduction in parasite burden and disease severity. In addition, treatment with the vaccine led to enhanced anti-<italic toggle="yes">Leishmania</italic> immune response, as evidenced by elevated Th1 activity and reduced levels of <italic toggle="yes">Leishmania</italic>-promoting Th2 and IL-10 [<xref rid="B109-microorganisms-08-01201" ref-type="bibr">109</xref>].</p></sec><sec id="sec4dot2-microorganisms-08-01201"><title>4.2. Cytokines and Chemokines</title><p>Cytokines and chemokines, which play key roles in immunity to <italic toggle="yes">Leishmania</italic> infection, have also been explored as potential immunotherapeutic agents. The use of recombinant IL-12 to treat <italic toggle="yes">L. major</italic>-infected BALB/c mice (at the time of infection) promoted parasite clearance and development of protective Th1 immune response [<xref rid="B113-microorganisms-08-01201" ref-type="bibr">113</xref>]. Immunotherapy using recombinant CXCL-10 either in the protein form alone or expressed in <italic toggle="yes">Leishmania tarentolae</italic> (a nonpathogenic <italic toggle="yes">Leishmania</italic>) was reported to show beneficial effects against <italic toggle="yes">L. major</italic> infection in BALB/c mice [<xref rid="B114-microorganisms-08-01201" ref-type="bibr">114</xref>]. The mice were treated with recombinant CXCL10 or <italic toggle="yes">L. tarentolae</italic> expressing CXCL-10 with or without adjuvant (CpG), and the effect was compared to treatment with amphotericin B. It was shown that the administration of CXCL10 expressing <italic toggle="yes">L. tarentolae</italic> along with adjuvant was effective against <italic toggle="yes">L. major</italic> although the effectiveness was less than that obtained with amphotericin B. In addition to a significant decrease in parasite burden, recombinant CXCL-10 treatment resulted in increased NO production, decreased arginase activity, and increased Th1 immune profile. Altogether, this study shows that <italic toggle="yes">L. tarentolae</italic>, a nonpathogenic specie of <italic toggle="yes">Leishmania</italic>, is a potential immunotherapeutic option for leishmaniasis and should be further explored to improve efficacy [<xref rid="B114-microorganisms-08-01201" ref-type="bibr">114</xref>]. Adipokine (leptin) has also been tested as a therapeutic agent for the treatment of leishmaniasis. The administration of adipokine led to reduced parasite burden in BALB/c mice with visceral leishmaniasis, and this was associated with increased protective host immune responses, such as increased IFN-&#947;, IL-12, and IL-2 production. Leptin treatment was also associated with the induction of granuloma in the liver, a process that contributes to parasite killing [<xref rid="B115-microorganisms-08-01201" ref-type="bibr">115</xref>].</p></sec><sec id="sec4dot3-microorganisms-08-01201"><title>4.3. Immune Checkpoint and Anti-Inflammatory Cytokine Inhibitors</title><p>Treatments which target immune suppressors such as PD-1 have been employed to control <italic toggle="yes">Leishmania</italic> infection in mouse models. In a 2019 study using BALB/c mice with nonhealing <italic toggle="yes">L. amazonensis</italic> infection, da Fonseca Martins et al. observed that anti-PD-1 and anti-PD-L1 monoclonal antibodies elicited a significant increase in IFN-&#947;-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells and resulted in increased control of infection in the BALB/c mice [<xref rid="B116-microorganisms-08-01201" ref-type="bibr">116</xref>]. Quirino et al. proposed that inhibition or blockade of IL-27 production could be an interesting target for future interventions in the context of visceral leishmaniasis. This is because IL-27 negatively regulates protective IL-17 production, leading to disease exacerbation [<xref rid="B117-microorganisms-08-01201" ref-type="bibr">117</xref>]. As well, inhibition of IL-10, a cytokine that is known to contribute to disease progression in leishmaniasis<italic toggle="yes">,</italic> has been reported to be beneficial in studies conducted in mouse models [<xref rid="B118-microorganisms-08-01201" ref-type="bibr">118</xref>] and patients [<xref rid="B119-microorganisms-08-01201" ref-type="bibr">119</xref>] with visceral leishmaniasis.</p></sec><sec id="sec4dot4-microorganisms-08-01201"><title>4.4. Inhibitors of Signalling Pathways</title><p>The use of inhibitors that target key pathways involved in immunoregulation has also shown some therapeutic potential against leishmaniasis. Khadem et al. reported that <italic toggle="yes">L. major</italic> and <italic toggle="yes">L. donovani</italic> infections can be treated through the administration of a p110&#948;-specific pharmacological inhibitor (CAL-101) either alone or in combination with amphotericin B [<xref rid="B120-microorganisms-08-01201" ref-type="bibr">120</xref>]. They observed a significant reduction in the cutaneous lesions (<italic toggle="yes">L. major</italic>) and parasite burdens in the spleens, livers, (<italic toggle="yes">L. donovani</italic>), and footpads (<italic toggle="yes">L. major</italic>) of infected mice, coinciding with reduced regulatory T cell (Treg) numbers. Their observations present a novel option for immunotherapy and the development of drugs/vaccines against leishmaniasis [<xref rid="B120-microorganisms-08-01201" ref-type="bibr">120</xref>]. Khadir et al. investigated the possibility of using mTOR inhibitors to treat <italic toggle="yes">L. major</italic> infection in mice. They found that mTOR inhibitors such as rapamycin and GSK-2126458 have immunomodulatory properties, leading to reduction in parasite load and effective control of disease progression [<xref rid="B121-microorganisms-08-01201" ref-type="bibr">121</xref>]. This observation suggests that rapamycin and perhaps GSK-2126458 are potential immunotherapeutic agents for the treatment of leishmaniasis [<xref rid="B121-microorganisms-08-01201" ref-type="bibr">121</xref>].</p></sec><sec id="sec4dot5-microorganisms-08-01201"><title>4.5. Modulation of Host Molecules</title><p>Host molecules may also be manipulated to influence the outcome of <italic toggle="yes">Leishmania</italic> infection. It has been reported that the deletion of liver X receptors (LXRs) gene, a host molecule that regulates the expression of genes involved in cholesterol and carbohydrate metabolism [<xref rid="B122-microorganisms-08-01201" ref-type="bibr">122</xref>], resulted in enhanced leishmanicidal capacity of their macrophages, leading to a significant decrease in parasite burden compared to WT mice [<xref rid="B123-microorganisms-08-01201" ref-type="bibr">123</xref>]. This study suggests that blockade of LXRs signaling may be a potential therapeutic approach in visceral leishmaniasis. Aryl hydrocarbon receptor (AhR), a transcription factor associated with inducing granuloma formation by macrophages [<xref rid="B124-microorganisms-08-01201" ref-type="bibr">124</xref>], was shown to be involved in <italic toggle="yes">Leishmania-</italic>induced secretion of tumor necrosis factor (TNF) from macrophages. The administration of AhR agonist locally at the site of infection resulted in a reduced Th2 response and a decrease in disease severity [<xref rid="B124-microorganisms-08-01201" ref-type="bibr">124</xref>]. This study suggests that AhR agonists may be a potential therapeutic agent against leishmaniasis. Recently, our lab showed that <italic toggle="yes">L. major</italic> infection was associated with a marked increase in the expression of long pentraxin-3 (PTX-3). The subsequent deletion of PTX-3 gene in the C57BL/6 mice resulted in enhanced resistance (reduced lesion size and parasite burden) following <italic toggle="yes">L. major</italic> infection. This was associated with significantly enhanced Th17/IL17 response, which we showed might be responsible for the enhanced resistance to <italic toggle="yes">L. major</italic> infection [<xref rid="B125-microorganisms-08-01201" ref-type="bibr">125</xref>]. This study suggests that neutralization of PTX-3 in infected individuals may potentially reduce the severity of the disease. Indeed, we found significantly higher levels of PTX-3 expression in skin biopsies of patients with active skin lesion caused by <italic toggle="yes">L. braziliensis</italic> infection. Treatment with chemotherapy significantly suppressed the expression of PTX-3 in these patients [<xref rid="B125-microorganisms-08-01201" ref-type="bibr">125</xref>]. In another recent study, we showed that Semaphorin-3E (Sema3E), a host molecule involved in axon guidance, was increased at the site of <italic toggle="yes">L. major</italic> infection. Targeted deletion of <italic toggle="yes">Sema3E</italic> gene resulted in increased Th1 response which might be responsible for the enhanced resistance (reduced lesion size and lower parasite burden) to <italic toggle="yes">L. major</italic> infection [<xref rid="B126-microorganisms-08-01201" ref-type="bibr">126</xref>]. This study suggests that neutralization of Sema3E in infected individuals may potentially result in better disease outcome.</p></sec><sec id="sec4dot6-microorganisms-08-01201"><title>4.6. Combination Therapies</title><p>Therapeutic regimens combining immunotherapy with other agents have also been tested for the treatment of leishmaniasis. Nascimento et al. compared treatment with allopurinol alone or in combination with a subunit vaccine from <italic toggle="yes">L. infantum</italic> formulated with a second-generation lipid adjuvant (SLA) in stable emulsion (SE), referred to as (Leish-F2 + SLA-SE). Allopurinol treatment reduced the disease severity, but the effect was not long-lasting. However, a combination of Leish-F2 + SLA-SE and allopurinol was able to provide long-lasting elimination of parasites (<italic toggle="yes">L. infantum</italic>) [<xref rid="B127-microorganisms-08-01201" ref-type="bibr">127</xref>]. Badaro et al. treated eight chemorefractory leishmaniasis patients with a combination of recombinant interferon gamma and conventional pentavalent antimonials. About 75% of these refractory patients responded to the combined treatment with fever as the only reported main adverse effect [<xref rid="B15-microorganisms-08-01201" ref-type="bibr">15</xref>]. Ghosh et al. showed the synergistic effect of sodium antimony gluconate and dendritic cells as viable options in immunotherapy against visceral leishmaniasis. They reported that the combined administration of bone marrow-derived dendritic cells pulsed with soluble <italic toggle="yes">L. donovani</italic> antigen (SLDA) and sodium antimony gluconate resulted in complete clearance of parasites in the liver and the spleen. This was associated with Th1 immune phenotype in the treated mice [<xref rid="B128-microorganisms-08-01201" ref-type="bibr">128</xref>]. Some of the immunotherapeutic agents that have been used in preclinical studies are summarized in <xref rid="microorganisms-08-01201-t002" ref-type="table">Table 2</xref>.</p></sec></sec><sec id="sec5-microorganisms-08-01201"><title>5. Perspective and Conclusions</title><p><italic toggle="yes">Leishmania</italic> parasites cause a range of debilitating diseases that affect millions of people and animals worldwide. This obligate intracellular organism interacts in dynamic ways with their mammalian host immune cells. <italic toggle="yes">Leishmania</italic> express thousands of antigens, have evolved to adapt to the harsh environment of the host cells, and can modulate host cell gene expression as needed. Hence, it is not surprising that they develop resistance to some currently available therapeutic agents. To complicate matters, many of the currently available drugs for treatment of leishmaniasis have serious side effects. Therefore, vaccination and immunotherapy are being considered for the treatment of leishmaniasis.</p><p>The immune response to leishmaniasis is complex, and significant advances have been made over the years in understanding the immunopathogenesis of the disease. It is known that <italic toggle="yes">Leishmania</italic> parasites reside in macrophages and that Th1 immune response is generally considered to be the major means of parasite clearance. However, the exact role of several immune cells, such as neutrophils, Th17 cells, and CD8<sup>+</sup> T cells, is still not clear. Furthermore, there is a need to better understand how <italic toggle="yes">Leishmania</italic> evades the host immune defenses and why vaccination has been relatively successful in mice and dogs but remains elusive in humans. A critical evaluation of the different vaccine studies shows that one of the possible contributing factors against successful vaccine development for humans is the use of highly susceptible BALB/c mice as a preclinical animal model for most of the vaccine design studies instead of the relatively resistant C57BL/6 mice that model human leishmaniasis. Another possible impediment to the development of human vaccine is the difficulty in finding appropriate adjuvants that can stimulate a strong cell-mediated immune response. The adjuvants that have been approved for use in humans, such as alum, MF59, ASo4, and ASo3, are poor in inducing strong and long-lasting T cell responses. A summary of key and immunotherapeutic strategies are illustrated in <xref ref-type="fig" rid="microorganisms-08-01201-f001">Figure 1</xref>.</p><p>Following inoculation into a mammalian host, <italic toggle="yes">Leishmania</italic> promastigotes infect several immune cells, including neutrophils, macrophages, and dendritic cells. The release of chemokines (e.g., MIP1&#946;, CCL3 &amp; IL-8) by infected neutrophils causes the recruitment of monocytes to the site of infection, and these differentiate into macrophages. In addition, infected neutrophils can also act as &#8220;Trojan horses,&#8221; thereby aiding and enhancing macrophage infection. The promastigotes develop into amastigotes in infected macrophages and perpetuate the infection. Infected dendritic cells (DCs) secrete IL-12, which activates NK cells and promotes differentiation of na&#239;ve CD4<sup>+</sup> T cells into Th1 cells. Activated NK cells and Th1 cells produce IFN-&#947;, which stimulates production of NO by infected macrophages, leading to parasite elimination. Through currently unknown regulatory mechanisms, the production of different cytokines (such as IL-4, IL-6, and TGF&#946;) by infected DCs favors the differentiation of na&#239;ve CD4<sup>+</sup> T cells into IL-4-producing Th2, IL-17-producing Th17, and IL-10-producing Treg cells. These cells may promote host resistance (Th17) or susceptibility (Th2, Th1,7 and Tregs) to <italic toggle="yes">Leishmania</italic>. Various immunotherapeutic strategies have been employed to boost or redirect the host immune response for effective therapeutic outcome against leishmaniasis. The blockade of LXRs leads to the death of parasite-harboring macrophages and a consequent reduction in parasite load and decreased disease severity. The administration of rCXCL-10, rIL-12, and adipokines, such as leptin, enhances IL-12 production, increases Th1 response, and increases IFN-&#947; and NO production, thereby promoting host resistance. The blockade of immune checkpoint inhibitors (by treatment anti-PD-1 and anti-PD-L1 mAb) or immune suppression (by anti-IL-10 mAb) increases the frequency of IFN- &#947; producing CD4<sup>+</sup> T cells, resulting in parasite clearance. Infection with <italic toggle="yes">Leishmania</italic> (<italic toggle="yes">L. major</italic>) leads to upregulation of Sema3E and PTX3 by several immune cells. The blockade of these molecules (as demonstrated by targeted gene deletion) provides novel strategy to enhance resistance following infection. The use of agonists (e.g., AhR agonist) to block the Th2 response and the use of p110&#948;-specific pharmacological inhibitor (CAL-101) to inhibit the differentiation and function of Tregs are all viable immunotherapeutic approaches that have shown some promise in preclinical studies.</p><p>Significant progress has been made in identifying potential immunotherapeutic candidates against various forms of leishmaniasis. However, more work needs to be done to translate these preclinical findings from mice to humans and other animals affected by the disease. Furthermore, results from some studies reviewed herein revealed that immunotherapy is still not as effective as conventional chemotherapy. This demonstrates the need for further research to improve the efficacy of immunotherapy and further explore the possibility of combining immunotherapy with chemotherapy for better disease outcome. In conclusion, we are of the opinion that the fight against leishmaniasis will encompass both vaccination and immunotherapy as both preventive and therapeutic approaches. We also opine that both strategies need to be effectively developed further to foster a synergistic two-faced arsenal against this neglected tropical disease with a potential for global impact.</p></sec></body><back><ack><title>Acknowledgments</title><p>Some figure elements were created using Biorender.com.</p></ack><notes><title>Author Contributions</title><p>Conceptualization N.M.I., C.A.E., C.O. and J.E.U. resources G.N.A. and E.S.S.; writing&#8212;original draft preparation N.M.I., G.N.A., C.A.E., E.S.S., C.O., A.F.B. and J.E.U. writing&#8212;review and editing N.M.I., G.N.A.., C.A.E., E.S.S., C.O., A.F.B. and J.E.U. supervision J.E.U. funding acquisition J.E.U. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by Canadian Institutes of Health Research (CIHR), grant number MOP114932 and Research Manitoba.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-microorganisms-08-01201"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Guerrero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Quintanilla-Cedillo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ruiz-Esmenjaud</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arenas</surname><given-names>R.</given-names></name></person-group><article-title>Leishmaniasis: A Review</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464238/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464238/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/f1000research.11120.1</pub-id><pub-id pub-id-type="pmcid">PMC5464238</pub-id><pub-id pub-id-type="pmid">28649370</pub-id></element-citation></ref><ref id="B2-microorganisms-08-01201"><label>2.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Leishmaniasis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/gho/neglected_diseases/leishmaniasis/en/">http://www.who.int/gho/neglected_diseases/leishmaniasis/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-02-05">(accessed on 5 February 2020)</date-in-citation></element-citation></ref><ref id="B3-microorganisms-08-01201"><label>3.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Ready</surname><given-names>P.D.</given-names></name></person-group><article-title>Epidemiology of Visceral Leishmaniasis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014360/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014360/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-02-28">(accessed on 28 February 2019)</date-in-citation></element-citation></ref><ref id="B4-microorganisms-08-01201"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>L.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Shanker</surname><given-names>V.</given-names></name><name name-style="western"><surname>Negi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matlashewski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>M.</given-names></name></person-group><article-title>Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>9</volume><elocation-id>e0006659</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006659</pub-id><pub-id pub-id-type="pmid">30260957</pub-id><pub-id pub-id-type="pmcid">PMC6159859</pub-id></element-citation></ref><ref id="B5-microorganisms-08-01201"><label>5.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Bahrami</surname><given-names>F.</given-names></name><name name-style="western"><surname>Harandi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S.</given-names></name></person-group><article-title>Biomarkers of Cutaneous Leishmaniasis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2018.00222/full">https://www.frontiersin.org/articles/10.3389/fcimb.2018.00222/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation></element-citation></ref><ref id="B6-microorganisms-08-01201"><label>6.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Cuba</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Llanos-Cuentas</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Magalh&#227;es</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lago</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>P.D.</given-names></name></person-group><article-title>Human Mucocutaneous Leishmaniasis in Tr&#234;s Bra&#231;os, Bahia-Brazil: An Area of Leishmania Braziliensis Braziliensis Transmission. I. Laboratory Diagnosis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.scielo.br/scielo.php?script=sci_abstract&amp;pid=S0037-86821984000400002&amp;lng=en&amp;nrm=iso&amp;tlng=en">http://www.scielo.br/scielo.php?script=sci_abstract&amp;pid=S0037-86821984000400002&amp;lng=en&amp;nrm=iso&amp;tlng=en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation></element-citation></ref><ref id="B7-microorganisms-08-01201"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.A.</given-names></name></person-group><article-title>The Parasite Causing Cutaneous Leishmaniasis in Ethiopia</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1973</year><volume>67</volume><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(73)90111-9</pub-id><pub-id pub-id-type="pmid">4778189</pub-id></element-citation></ref><ref id="B8-microorganisms-08-01201"><label>8.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Bates</surname><given-names>P.A.</given-names></name></person-group><article-title>Revising Leishmania&#8217;s Life Cycle</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41564-018-0154-2">https://www.nature.com/articles/s41564-018-0154-2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation></element-citation></ref><ref id="B9-microorganisms-08-01201"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiner</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Locksley</surname><given-names>R.M.</given-names></name></person-group><article-title>The regulation of immunity to Leishmania major</article-title><source>Annu. Rev. Immunol.</source><year>1995</year><volume>13</volume><fpage>151</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.13.040195.001055</pub-id><pub-id pub-id-type="pmid">7612219</pub-id></element-citation></ref><ref id="B10-microorganisms-08-01201"><label>10.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Sunter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gull</surname><given-names>K.</given-names></name></person-group><article-title>Shape, Form, Function and Leishmania Pathogenicity: From Textbook Descriptions to Biological Understanding</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://royalsocietypublishing.org/doi/10.1098/rsob.170165">https://royalsocietypublishing.org/doi/10.1098/rsob.170165</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation></element-citation></ref><ref id="B11-microorganisms-08-01201"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamhawi</surname><given-names>S.</given-names></name></person-group><article-title>The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections</article-title><source>Microbes Infect.</source><year>2000</year><volume>2</volume><fpage>1765</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(00)01331-9</pub-id><pub-id pub-id-type="pmid">11137049</pub-id></element-citation></ref><ref id="B12-microorganisms-08-01201"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name><name name-style="western"><surname>Artis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Uzonna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zaph</surname><given-names>C.</given-names></name></person-group><article-title>The development of effector and memory T cells in cutaneous leishmaniasis: The implications for vaccine development</article-title><source>Immunol. Rev.</source><year>2004</year><volume>201</volume><fpage>318</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00198.x</pub-id><pub-id pub-id-type="pmid">15361250</pub-id></element-citation></ref><ref id="B13-microorganisms-08-01201"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keynan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Larios</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Plourde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ouellette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>E.</given-names></name></person-group><article-title>Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan</article-title><source>Can. J. Infect. Dis. Med. Microbiol.</source><year>2008</year><volume>19</volume><fpage>394</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1155/2008/802710</pub-id><pub-id pub-id-type="pmid">19436567</pub-id><pub-id pub-id-type="pmcid">PMC2663468</pub-id></element-citation></ref><ref id="B14-microorganisms-08-01201"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novais</surname><given-names>F.O.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>B&#225;fica</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khouri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Afonso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>C.I.</given-names></name></person-group><article-title>Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>8088</fpage><lpage>8098</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803720</pub-id><pub-id pub-id-type="pmid">19923470</pub-id></element-citation></ref><ref id="B15-microorganisms-08-01201"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badaro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Falcoff</surname><given-names>E.</given-names></name><name name-style="western"><surname>Badaro</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Pedral-Sampaio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bina</surname><given-names>J.C.</given-names></name></person-group><article-title>Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma</article-title><source>New Engl. J. Med.</source><year>1990</year><volume>322</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJM199001043220104</pub-id><pub-id pub-id-type="pmid">2104665</pub-id></element-citation></ref><ref id="B16-microorganisms-08-01201"><label>16.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olliaro</surname><given-names>P.L.</given-names></name></person-group><article-title>Miltefosine in the Treatment of Leishmaniasis: Clinical Evidence for Informed Clinical Risk Management</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376078/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376078/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="pmcid">PMC2376078</pub-id><pub-id pub-id-type="pmid">18472998</pub-id></element-citation></ref><ref id="B17-microorganisms-08-01201"><label>17.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Aronson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herwaldt</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Libman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lopez-Velez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ephros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jeronimo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magill</surname><given-names>A.</given-names></name></person-group><article-title>Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239701/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239701/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.16-84256</pub-id><pub-id pub-id-type="pmcid">PMC5239701</pub-id><pub-id pub-id-type="pmid">27927991</pub-id></element-citation></ref><ref id="B18-microorganisms-08-01201"><label>18.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bilbe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blesson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Monnerat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mowbray</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ouattara</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>P&#233;coul</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rijal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rode</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cmr.asm.org/content/31/4/e00048-18">https://cmr.asm.org/content/31/4/e00048-18</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00048-18</pub-id><pub-id pub-id-type="pmcid">PMC6148188</pub-id><pub-id pub-id-type="pmid">30158301</pub-id></element-citation></ref><ref id="B19-microorganisms-08-01201"><label>19.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Balasegaram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ritmeijer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Burza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ortiz Genovese</surname><given-names>G.</given-names></name><name name-style="western"><surname>Milani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gaspani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Potet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chappuis</surname><given-names>F.</given-names></name></person-group><article-title>Liposomal Amphotericin B as a Treatment for Human Leishmaniasis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518293/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518293/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-03-05">(accessed on 5 March 2019)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14728214.2012.748036</pub-id><pub-id pub-id-type="pmcid">PMC3518293</pub-id><pub-id pub-id-type="pmid">23167833</pub-id></element-citation></ref><ref id="B20-microorganisms-08-01201"><label>20.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Goyonlo</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Vosoughi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kiafar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nahidi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Momenzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>A.R.</given-names></name></person-group><article-title>Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248523/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248523/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-05-29">(accessed on 29 May 2019)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0019-5154.143571</pub-id><pub-id pub-id-type="pmcid">PMC4248523</pub-id><pub-id pub-id-type="pmid">25484415</pub-id></element-citation></ref><ref id="B21-microorganisms-08-01201"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>J.J.</given-names></name></person-group><article-title>Treatment of leishmaniasis with miltefosine: 2008 status</article-title><source>Expert Opin. Drug. Metab. Toxicol.</source><year>2008</year><volume>4</volume><fpage>1209</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1517/17425255.4.9.1209</pub-id><pub-id pub-id-type="pmid">18721114</pub-id></element-citation></ref><ref id="B22-microorganisms-08-01201"><label>22.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Sunyoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Potet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boelaert</surname><given-names>M.</given-names></name></person-group><article-title>Why Miltefosine&#8212;A Life-Saving Drug for Leishmaniasis&#8212;Is Unavailable to People Who Need It the Most</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935166/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935166/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjgh-2018-000709</pub-id><pub-id pub-id-type="pmcid">PMC5935166</pub-id><pub-id pub-id-type="pmid">29736277</pub-id></element-citation></ref><ref id="B23-microorganisms-08-01201"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Durdu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Culha</surname><given-names>G.</given-names></name><name name-style="western"><surname>Allahverdiyev</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Memisoglu</surname><given-names>H.R.</given-names></name></person-group><article-title>Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: Recent experience in Turkey</article-title><source>J. Parasitol.</source><year>2004</year><volume>90</volume><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1645/GE-185R</pub-id><pub-id pub-id-type="pmid">15357081</pub-id></element-citation></ref><ref id="B24-microorganisms-08-01201"><label>24.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Peniche</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Melby</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Travi</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>E.Y.</given-names></name></person-group><article-title>A Secondary Wave of Neutrophil Infiltration Causes Necrosis and Ulceration in Lesions of Experimental American Cutaneous Leishmaniasis</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179084">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179084</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-05-30">(accessed on 30 May 2019)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0179084</pub-id><pub-id pub-id-type="pmcid">PMC5462435</pub-id><pub-id pub-id-type="pmid">28591228</pub-id></element-citation></ref><ref id="B25-microorganisms-08-01201"><label>25.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Costa-da-Silva</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>DosReis</surname><given-names>G.A.</given-names></name></person-group><article-title>Innate Immunity to Leishmania Infection: Within Phagocytes</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119695/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119695/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-07">(accessed on 7 May 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/754965</pub-id><pub-id pub-id-type="pmcid">PMC4119695</pub-id><pub-id pub-id-type="pmid">25110400</pub-id></element-citation></ref><ref id="B26-microorganisms-08-01201"><label>26.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fasel</surname><given-names>N.</given-names></name></person-group><article-title>How to Master the Host Immune System? Leishmania Parasites have the Solutions!</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892169/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892169/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxx075</pub-id><pub-id pub-id-type="pmcid">PMC5892169</pub-id><pub-id pub-id-type="pmid">29294040</pub-id></element-citation></ref><ref id="B27-microorganisms-08-01201"><label>27.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Nyl&#233;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>S.</given-names></name></person-group><article-title>Immunological Perspectives of Leishmaniasis</article-title><year>2010</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889653/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889653/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0974-777X.62876</pub-id><pub-id pub-id-type="pmcid">PMC2889653</pub-id><pub-id pub-id-type="pmid">20606969</pub-id></element-citation></ref><ref id="B28-microorganisms-08-01201"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurrell</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Regli</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Tacchini-Cottier</surname><given-names>F.</given-names></name></person-group><article-title>Different Leishmania Species Drive Distinct Neutrophil Functions</article-title><source>Trends Parasitol.</source><year>2016</year><volume>32</volume><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2016.02.003</pub-id><pub-id pub-id-type="pmid">26944469</pub-id></element-citation></ref><ref id="B29-microorganisms-08-01201"><label>29.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Oualha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barhoumi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marzouki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harigua-Souiai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ben Ahmed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guizani</surname><given-names>I.</given-names></name></person-group><article-title>Infection of Human Neutrophils with Leishmania infantum or Leishmania Major Strains Triggers Activation and Differential Cytokines Release</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2019.00153/full">https://www.frontiersin.org/articles/10.3389/fcimb.2019.00153/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2019.00153</pub-id><pub-id pub-id-type="pmcid">PMC6524560</pub-id><pub-id pub-id-type="pmid">31134162</pub-id></element-citation></ref><ref id="B30-microorganisms-08-01201"><label>30.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Wardini</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Pinto-da-Silva</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Nadaes</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Roatt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Viana</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Giunchetti</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>E.M.</given-names></name></person-group><article-title>Neutrophil Properties in Healthy and Leishmania Infantum-Naturally Infected Dogs</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41598-019-42687-9">https://www.nature.com/articles/s41598-019-42687-9</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-42687-9</pub-id><pub-id pub-id-type="pmcid">PMC6472404</pub-id><pub-id pub-id-type="pmid">31000764</pub-id></element-citation></ref><ref id="B31-microorganisms-08-01201"><label>31.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Millott</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parkinson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Moncada</surname><given-names>S.</given-names></name></person-group><article-title>Macrophage Killing of Leishmania Parasite In Vivo Is Mediated by Nitric Oxide from L-Arginine</article-title><year>1990</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.jimmunol.org/content/144/12/4794">https://www.jimmunol.org/content/144/12/4794</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-06-21">(accessed on 21 June 2019)</date-in-citation><pub-id pub-id-type="pmid">2351828</pub-id></element-citation></ref><ref id="B32-microorganisms-08-01201"><label>32.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Carneiro</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Concei&#231;&#227;o</surname><given-names>J.</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Magalh&#227;es</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bacellar</surname><given-names>O.</given-names></name></person-group><article-title>The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of Leishmania braziliensis by Monocytes from Patients with Cutaneous Leishmaniasis</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739692/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739692/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0148084</pub-id><pub-id pub-id-type="pmcid">PMC4739692</pub-id><pub-id pub-id-type="pmid">26840253</pub-id></element-citation></ref><ref id="B33-microorganisms-08-01201"><label>33.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Acu&#241;a</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Laranjeira-Silva</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Zampieri</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>J.C.R.</given-names></name><name name-style="western"><surname>Muxel</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Floeter-Winter</surname><given-names>L.M.</given-names></name></person-group><article-title>Arginase Expression Modulates Nitric Oxide Production in Leishmania (Leishmania) Amazonensis</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187186">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187186</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0187186</pub-id><pub-id pub-id-type="pmcid">PMC5685479</pub-id><pub-id pub-id-type="pmid">29135983</pub-id></element-citation></ref><ref id="B34-microorganisms-08-01201"><label>34.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Vouldoukis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Riveros-Moreno</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dugas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ouaaz</surname><given-names>F.</given-names></name><name name-style="western"><surname>B&#233;cherel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Debr&#233;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moncada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mossalayi</surname><given-names>M.D.</given-names></name></person-group><article-title>The Killing of Leishmania Major by Human Macrophages Is Mediated by Nitric Oxide Induced after Ligation of the Fc Epsilon RII/CD23 Surface Antigen</article-title><year>1995</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pnas.org/content/92/17/7804">https://www.pnas.org/content/92/17/7804</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.92.17.7804</pub-id><pub-id pub-id-type="pmcid">PMC41234</pub-id><pub-id pub-id-type="pmid">7544003</pub-id></element-citation></ref><ref id="B35-microorganisms-08-01201"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charmoy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Megnekou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Allenbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zweifel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monnat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ronet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Launois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tacchini-Cottier</surname><given-names>F.</given-names></name></person-group><article-title>Leishmania major induces distinct neutrophil phenotypes in mice that are resistant or susceptible to infection</article-title><source>J. Leukoc. Biol.</source><year>2007</year><volume>82</volume><fpage>288</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1189/jlb.0706440</pub-id><pub-id pub-id-type="pmid">17449725</pub-id></element-citation></ref><ref id="B36-microorganisms-08-01201"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faber</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Oskam</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Gool</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>N.C.M.</given-names></name><name name-style="western"><surname>Knegt-Junk</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Hofwegen</surname><given-names>H.</given-names></name><name name-style="western"><surname>van der Wal</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Kager</surname><given-names>P.A.</given-names></name></person-group><article-title>Value of diagnostic techniques for cutaneous leishmaniasis</article-title><source>J. Am. Acad. Dermatol.</source><year>2003</year><volume>49</volume><fpage>70</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1067/mjd.2003.492</pub-id><pub-id pub-id-type="pmid">12833011</pub-id></element-citation></ref><ref id="B37-microorganisms-08-01201"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Von Stebut</surname><given-names>E.</given-names></name><name name-style="western"><surname>Metz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Milon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Knop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>M.</given-names></name></person-group><article-title>Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1alpha /beta released from neutrophils recruited by mast cell-derived TNFalpha</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-03-0921</pub-id><pub-id pub-id-type="pmid">12393677</pub-id></element-citation></ref><ref id="B38-microorganisms-08-01201"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Zandbergen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laufs</surname><given-names>H.</given-names></name><name name-style="western"><surname>Solbach</surname><given-names>W.</given-names></name><name name-style="western"><surname>Laskay</surname><given-names>T.</given-names></name></person-group><article-title>Leishmania Promastigotes Release a Granulocyte Chemotactic Factor and Induce Interleukin-8 Release but Inhibit Gamma Interferon-Inducible Protein 10 Production by Neutrophil Granulocytes</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>4177</fpage><lpage>4184</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.8.4177-4184.2002</pub-id><pub-id pub-id-type="pmid">12117926</pub-id><pub-id pub-id-type="pmcid">PMC128123</pub-id></element-citation></ref><ref id="B39-microorganisms-08-01201"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laskay</surname><given-names>T.</given-names></name><name name-style="western"><surname>van Zandbergen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Solbach</surname><given-names>W.</given-names></name></person-group><article-title>Neutrophil granulocytes&#8212;Trojan horses for Leishmania major and other intracellular microbes?</article-title><source>Trends Microbiol.</source><year>2003</year><volume>11</volume><fpage>210</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(03)00075-1</pub-id><pub-id pub-id-type="pmid">12781523</pub-id></element-citation></ref><ref id="B40-microorganisms-08-01201"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Egen</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Secundino</surname><given-names>N.</given-names></name><name name-style="western"><surname>Debrabant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kimblin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kamhawi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawyer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fay</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>In vivo imaging reveals an essential role for neutrophils in Leishmaniasis transmitted by sand flies</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>970</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1126/science.1159194</pub-id><pub-id pub-id-type="pmid">18703742</pub-id><pub-id pub-id-type="pmcid">PMC2606057</pub-id></element-citation></ref><ref id="B41-microorganisms-08-01201"><label>41.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Soulat</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name></person-group><article-title>Function of Macrophage and Parasite Phosphatases in Leishmaniasis. Front Immunol</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2017.01838/full">https://www.frontiersin.org/articles/10.3389/fimmu.2017.01838/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01838</pub-id><pub-id pub-id-type="pmcid">PMC5743797</pub-id><pub-id pub-id-type="pmid">29312331</pub-id></element-citation></ref><ref id="B42-microorganisms-08-01201"><label>42.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Tomiotto-Pellissier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bortoleti</surname><given-names>B.T.d.S.</given-names></name><name name-style="western"><surname>Assolini</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Carloto</surname><given-names>A.C.M.</given-names></name><name name-style="western"><surname>Miranda-Sapla</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Conchon-Costa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bordignon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pavanelli</surname><given-names>W.R.</given-names></name></person-group><article-title>Macrophage Polarization in Leishmaniasis: Broadening Horizons</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220043/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220043/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02529</pub-id><pub-id pub-id-type="pmcid">PMC6220043</pub-id><pub-id pub-id-type="pmid">30429856</pub-id></element-citation></ref><ref id="B43-microorganisms-08-01201"><label>43.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Jayakumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Widenmaier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>McDowell</surname><given-names>M.A.</given-names></name></person-group><article-title>Transcriptional Inhibition of Interleukin-12 Promoter Activity in Leishmania spp.-Infected Macrophages</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2665708/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2665708/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1645/GE-1153.1</pub-id><pub-id pub-id-type="pmcid">PMC2665708</pub-id><pub-id pub-id-type="pmid">18372625</pub-id></element-citation></ref><ref id="B44-microorganisms-08-01201"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>dos Santos Maciel</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Venturin</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Bragato</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rebech</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>de Oliveira Santos</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>B.M.N.</given-names></name><name name-style="western"><surname>de S&#225; Oliveira</surname><given-names>G.G.</given-names></name><etal/></person-group><article-title>Combined in vitro IL-12 and IL-15 stimulation promotes cellular immune response in dogs with visceral leishmaniasis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2020</year><volume>14</volume><elocation-id>e0008021</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0008021</pub-id><pub-id pub-id-type="pmid">31961868</pub-id><pub-id pub-id-type="pmcid">PMC7006941</pub-id></element-citation></ref><ref id="B45-microorganisms-08-01201"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Hondowicz</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>IL-12 Is Required to Maintain a Th1 Response during Leishmania major Infection</article-title><source>J. Immunol.</source><year>2000</year><volume>165</volume><fpage>896</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.2.896</pub-id><pub-id pub-id-type="pmid">10878364</pub-id></element-citation></ref><ref id="B46-microorganisms-08-01201"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Hondowicz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kopf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>The role of IL-12 in maintaining resistance to Leishmania major</article-title><source>J. Immunol.</source><year>2002</year><volume>168</volume><fpage>5771</fpage><lpage>5777</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.11.5771</pub-id><pub-id pub-id-type="pmid">12023378</pub-id></element-citation></ref><ref id="B47-microorganisms-08-01201"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wanderley</surname><given-names>J.L.M.</given-names></name><name name-style="western"><surname>Deolindo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Portugal</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>DaMatta</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Barcinski</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Soong</surname><given-names>L.</given-names></name></person-group><article-title>CD4<sup>+</sup> T Cell-Dependent Macrophage Activation Modulates Sustained PS Exposure on Intracellular Amastigotes of Leishmania amazonensis</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00105</pub-id><pub-id pub-id-type="pmid">31032234</pub-id><pub-id pub-id-type="pmcid">PMC6473175</pub-id></element-citation></ref><ref id="B48-microorganisms-08-01201"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;lscher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arendse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schwegmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Myburgh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brombacher</surname><given-names>F.</given-names></name></person-group><article-title>Impairment of Alternative Macrophage Activation Delays Cutaneous Leishmaniasis in Nonhealing BALB/c Mice</article-title><source>J. Immunol.</source><year>2006</year><volume>176</volume><fpage>1115</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.2.1115</pub-id><pub-id pub-id-type="pmid">16394000</pub-id></element-citation></ref><ref id="B49-microorganisms-08-01201"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lecoeur</surname><given-names>H.</given-names></name><name name-style="western"><surname>Prina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rosazza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kokou</surname><given-names>K.</given-names></name><name name-style="western"><surname>N&#8217;Diaye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aulner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Varet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bussotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Milon</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-&#954;B/NLRP3-Mediated Inflammatory Response</article-title><source>Cell Rep.</source><year>2020</year><volume>30</volume><fpage>1870</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.01.030</pub-id><pub-id pub-id-type="pmid">32049017</pub-id></element-citation></ref><ref id="B50-microorganisms-08-01201"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Millott</surname><given-names>S.</given-names></name></person-group><article-title>Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine</article-title><source>Immunology</source><year>1990</year><volume>71</volume><fpage>556</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">2279740</pub-id><pub-id pub-id-type="pmcid">PMC1384878</pub-id></element-citation></ref><ref id="B51-microorganisms-08-01201"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Godbout</surname><given-names>M.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Forget</surname><given-names>G.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name></person-group><article-title>A novel form of NF-kappaB is induced by Leishmania infection: Involvement in macrophage gene expression</article-title><source>Eur. J. Immunol.</source><year>2008</year><volume>38</volume><fpage>1071</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1002/eji.200737586</pub-id><pub-id pub-id-type="pmid">18383035</pub-id></element-citation></ref><ref id="B52-microorganisms-08-01201"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name><name name-style="western"><surname>R&#246;llinghoff</surname><given-names>M.</given-names></name></person-group><article-title>How do Protozoan Parasites Survive inside Macrophages?</article-title><source>Parasitol. Today</source><year>1999</year><volume>15</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/S0169-4758(98)01362-3</pub-id><pub-id pub-id-type="pmid">10234174</pub-id></element-citation></ref><ref id="B53-microorganisms-08-01201"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wanasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Soong</surname><given-names>L.</given-names></name></person-group><article-title>L-arginine metabolism and its impact on host immunity against Leishmania infection</article-title><source>Immunol. Res.</source><year>2008</year><volume>41</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s12026-007-8012-y</pub-id><pub-id pub-id-type="pmid">18040886</pub-id><pub-id pub-id-type="pmcid">PMC2639710</pub-id></element-citation></ref><ref id="B54-microorganisms-08-01201"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ure</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moncada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>F.Y.</given-names></name></person-group><article-title>Altered immune responses in mice lacking inducible nitric oxide synthase</article-title><source>Nature</source><year>1995</year><volume>375</volume><fpage>408</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/375408a0</pub-id><pub-id pub-id-type="pmid">7539113</pub-id></element-citation></ref><ref id="B55-microorganisms-08-01201"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gantt</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jeronimo</surname><given-names>S.M.B.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Britigan</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.E.</given-names></name></person-group><article-title>Oxidative Responses of Human and Murine Macrophages During Phagocytosis of <italic toggle="yes">Leishmania chagasi</italic></article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>893</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.2.893</pub-id><pub-id pub-id-type="pmid">11441096</pub-id></element-citation></ref><ref id="B56-microorganisms-08-01201"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Donhauser</surname><given-names>N.</given-names></name><name name-style="western"><surname>Th&#252;ring</surname><given-names>H.</given-names></name><name name-style="western"><surname>R&#246;llinghoff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name></person-group><article-title>Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase</article-title><source>J. Exp. Med.</source><year>1996</year><volume>183</volume><fpage>1501</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1084/jem.183.4.1501</pub-id><pub-id pub-id-type="pmid">8666908</pub-id><pub-id pub-id-type="pmcid">PMC2192515</pub-id></element-citation></ref><ref id="B57-microorganisms-08-01201"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cassatella</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Costantini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jaillon</surname><given-names>S.</given-names></name></person-group><article-title>Neutrophils in the activation and regulation of innate and adaptive immunity</article-title><source>Nat. Rev. Immunol.</source><year>2011</year><volume>11</volume><fpage>519</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1038/nri3024</pub-id><pub-id pub-id-type="pmid">21785456</pub-id></element-citation></ref><ref id="B58-microorganisms-08-01201"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>M.B.H.</given-names></name><name name-style="western"><surname>Doria</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Roma</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Ribeiro-Gomes</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Inbar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Divergent roles for Ly6C+CCR2+CX3CR1+ inflammatory monocytes during primary or secondary infection of the skin with the intra-phagosomal pathogen Leishmania major</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><elocation-id>e1006479</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006479</pub-id><pub-id pub-id-type="pmid">28666021</pub-id><pub-id pub-id-type="pmcid">PMC5509374</pub-id></element-citation></ref><ref id="B59-microorganisms-08-01201"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soong</surname><given-names>L.</given-names></name></person-group><article-title>Modulation of Dendritic Cell Function by Leishmania Parasites</article-title><source>J. Immunol.</source><year>2008</year><volume>180</volume><fpage>4355</fpage><lpage>4360</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.7.4355</pub-id><pub-id pub-id-type="pmid">18354154</pub-id><pub-id pub-id-type="pmcid">PMC2639709</pub-id></element-citation></ref><ref id="B60-microorganisms-08-01201"><label>60.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Feij&#243;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tib&#250;rcio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ampuero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brodskyn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>N.</given-names></name></person-group><article-title>Dendritic Cells and Leishmania Infection: Adding Layers of Complexity to a Complex Disease</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745329/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745329/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/3967436</pub-id><pub-id pub-id-type="pmcid">PMC4745329</pub-id><pub-id pub-id-type="pmid">26904694</pub-id></element-citation></ref><ref id="B61-microorganisms-08-01201"><label>61.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Tib&#250;rcio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rosa Ampuero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Machado Tavares</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brodskyn</surname><given-names>C.</given-names></name></person-group><article-title>Molecular Aspects of Dendritic Cell Activation in Leishmaniasis: An Immunobiological View</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.00227/full">https://www.frontiersin.org/articles/10.3389/fimmu.2019.00227/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00227</pub-id><pub-id pub-id-type="pmcid">PMC6401646</pub-id><pub-id pub-id-type="pmid">30873156</pub-id></element-citation></ref><ref id="B62-microorganisms-08-01201"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abidin</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Heinonen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>St&#228;ger</surname><given-names>S.</given-names></name></person-group><article-title>HIF-1&#945; hampers dendritic cell function and Th1 generation during chronic visceral leishmaniasis</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>3500</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-21891-z</pub-id><pub-id pub-id-type="pmid">29472618</pub-id><pub-id pub-id-type="pmcid">PMC5823892</pub-id></element-citation></ref><ref id="B63-microorganisms-08-01201"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contreras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Estrada</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Guak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Martel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borjian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ralph</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shio</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name></person-group><article-title>Impact of Leishmania mexicana Infection on Dendritic Cell Signaling and Functions</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e3202</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003202</pub-id><pub-id pub-id-type="pmid">25255446</pub-id><pub-id pub-id-type="pmcid">PMC4177750</pub-id></element-citation></ref><ref id="B64-microorganisms-08-01201"><label>64.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brombacher</surname><given-names>F.</given-names></name></person-group><article-title>T Helper1/T Helper2 Cells and Resistance/Susceptibility to Leishmania Infection: Is This Paradigm Still Relevant?</article-title><year>2012</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2012.00080/full">https://www.frontiersin.org/articles/10.3389/fimmu.2012.00080/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2012.00080</pub-id><pub-id pub-id-type="pmcid">PMC3342373</pub-id><pub-id pub-id-type="pmid">22566961</pub-id></element-citation></ref><ref id="B65-microorganisms-08-01201"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>P.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kushawaha</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dube</surname><given-names>A.</given-names></name></person-group><article-title>Th1 Stimulatory Proteins of Leishmania donovani: Comparative Cellular and Protective Responses of rTriose Phosphate Isomerase, rProtein Disulfide Isomerase and rElongation Factor-2 in Combination with rHSP70 against Visceral Leishmaniasis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e108556</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0108556</pub-id><pub-id pub-id-type="pmid">25268700</pub-id><pub-id pub-id-type="pmcid">PMC4182492</pub-id></element-citation></ref><ref id="B66-microorganisms-08-01201"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miralles</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Stoeckle</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Finkelman</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>H.W.</given-names></name></person-group><article-title>Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis</article-title><source>Infect. Immun.</source><year>1994</year><volume>62</volume><fpage>1058</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1128/IAI.62.3.1058-1063.1994</pub-id><pub-id pub-id-type="pmid">8112840</pub-id><pub-id pub-id-type="pmcid">PMC186224</pub-id></element-citation></ref><ref id="B67-microorganisms-08-01201"><label>67.</label><element-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Dayakar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandrasekaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuchipudi</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Kalangi</surname><given-names>S.K.</given-names></name></person-group><article-title>Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.00670/full">https://www.frontiersin.org/articles/10.3389/fimmu.2019.00670/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-14">(accessed on 14 July 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00670</pub-id><pub-id pub-id-type="pmcid">PMC6459942</pub-id><pub-id pub-id-type="pmid">31024534</pub-id></element-citation></ref><ref id="B68-microorganisms-08-01201"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marovich</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>McDowell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>T.B.</given-names></name></person-group><article-title>IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process</article-title><source>J. Immunol.</source><year>2000</year><volume>164</volume><fpage>5858</fpage><lpage>5865</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.11.5858</pub-id><pub-id pub-id-type="pmid">10820265</pub-id></element-citation></ref><ref id="B69-microorganisms-08-01201"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelsall</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>St&#252;ber</surname><given-names>E.</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strober</surname><given-names>W.</given-names></name></person-group><article-title>Interleukin-12 production by dendritic cells: The role of CD40-CD40L interactions in Th1 T-cell responses</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1996</year><volume>795</volume><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1996.tb52660.x</pub-id><pub-id pub-id-type="pmid">8958922</pub-id></element-citation></ref><ref id="B70-microorganisms-08-01201"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okwor</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Uzonna</surname><given-names>J.E.</given-names></name></person-group><article-title>Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major</article-title><source>J. Immunol.</source><year>2015</year><volume>195</volume><fpage>3218</fpage><lpage>3226</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500922</pub-id><pub-id pub-id-type="pmid">26304989</pub-id></element-citation></ref><ref id="B71-microorganisms-08-01201"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamanaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kikutani</surname><given-names>H.</given-names></name></person-group><article-title>Protective Role of CD40 in Leishmania major Infection at Two Distinct Phases of Cell-Mediated Immunity</article-title><source>Immunity</source><year>1996</year><volume>4</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80435-5</pub-id><pub-id pub-id-type="pmid">8624817</pub-id></element-citation></ref><ref id="B72-microorganisms-08-01201"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hathcock</surname><given-names>K.</given-names></name><name name-style="western"><surname>Laszlo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pucillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linsley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hodes</surname><given-names>R.J.</given-names></name></person-group><article-title>Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function</article-title><source>J. Exp. Med.</source><year>1994</year><volume>180</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1084/jem.180.2.631</pub-id><pub-id pub-id-type="pmid">7519245</pub-id><pub-id pub-id-type="pmcid">PMC2191623</pub-id></element-citation></ref><ref id="B73-microorganisms-08-01201"><label>73.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name></person-group><article-title>Natural Killer Cells in Experimental and Human Leishmaniasis</article-title><year>2012</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417408/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417408/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-24">(accessed on 24 June 2020)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2012.00069</pub-id><pub-id pub-id-type="pmcid">PMC3417408</pub-id><pub-id pub-id-type="pmid">22919660</pub-id></element-citation></ref><ref id="B74-microorganisms-08-01201"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prajeeth</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sebald</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schleicher</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name></person-group><article-title>Leishmania-Infected Macrophages Are Targets of NK Cell-Derived Cytokines but Not of NK Cell Cytotoxicity</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>2699</fpage><lpage>2708</lpage><pub-id pub-id-type="doi">10.1128/IAI.00079-11</pub-id><pub-id pub-id-type="pmid">21518784</pub-id><pub-id pub-id-type="pmcid">PMC3191990</pub-id></element-citation></ref><ref id="B75-microorganisms-08-01201"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ca&#241;eda-Guzm&#225;n</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Salaiza-Suazo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Figueroa</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Carrada-Figueroa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aguirre-Garc&#237;a</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>I.N.K.</given-names></name></person-group><article-title>Cell Activity Differs between Patients with Localized and Diffuse Cutaneous Leishmaniasis Infected with Leishmania mexicana: A Comparative Study of TLRs and Cytokines</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e112410</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0112410</pub-id><pub-id pub-id-type="pmid">25397678</pub-id><pub-id pub-id-type="pmcid">PMC4232367</pub-id></element-citation></ref><ref id="B76-microorganisms-08-01201"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Zandbergen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laufs</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jahnke</surname><given-names>N.</given-names></name><name name-style="western"><surname>Solbach</surname><given-names>W.</given-names></name><name name-style="western"><surname>Laskay</surname><given-names>T.</given-names></name></person-group><article-title>Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice</article-title><source>Med. Microbiol. Immunol.</source><year>2001</year><volume>190</volume><fpage>73</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s004300100084</pub-id><pub-id pub-id-type="pmid">11770115</pub-id></element-citation></ref><ref id="B77-microorganisms-08-01201"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice</article-title><source>J. Exp. Med.</source><year>1993</year><volume>178</volume><fpage>567</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1084/jem.178.2.567</pub-id><pub-id pub-id-type="pmid">8101861</pub-id><pub-id pub-id-type="pmcid">PMC2191131</pub-id></element-citation></ref><ref id="B78-microorganisms-08-01201"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name><name name-style="western"><surname>Novais</surname><given-names>F.O.</given-names></name></person-group><article-title>Cutaneous leishmaniasis: Immune responses in protection and pathogenesis</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>581</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.72</pub-id><pub-id pub-id-type="pmid">27424773</pub-id></element-citation></ref><ref id="B79-microorganisms-08-01201"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacchini-Cottier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zweifel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mukankundiye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vasei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Launois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Milon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Louis</surname><given-names>J.A.</given-names></name></person-group><article-title>An immunomodulatory function for neutrophils during the induction of a CD4<sup>+</sup> Th2 response in BALB/c mice infected with Leishmania major</article-title><source>J. Immunol.</source><year>2000</year><volume>165</volume><fpage>2628</fpage><lpage>2636</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.5.2628</pub-id><pub-id pub-id-type="pmid">10946291</pub-id></element-citation></ref><ref id="B80-microorganisms-08-01201"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Lombana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gimblet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bacellar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Passos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Goldschmidt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003243</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003243</pub-id><pub-id pub-id-type="pmid">23555256</pub-id><pub-id pub-id-type="pmcid">PMC3605236</pub-id></element-citation></ref><ref id="B81-microorganisms-08-01201"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>M.S.L.</given-names></name><name name-style="western"><surname>Carregaro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lima-J&#250;nior</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Ryffel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>de Jesus</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Almeida</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>J.S.</given-names></name></person-group><article-title>Interleukin 17A acts synergistically with interferon &#947; to promote protection against <italic toggle="yes">Leishmania infantum</italic> infection</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>211</volume><fpage>1015</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu531</pub-id><pub-id pub-id-type="pmid">25274569</pub-id></element-citation></ref><ref id="B82-microorganisms-08-01201"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitta</surname><given-names>M.G.R.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cabantous</surname><given-names>S.</given-names></name><name name-style="western"><surname>Henri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kouriba</surname><given-names>B.</given-names></name><name name-style="western"><surname>Argiro</surname><given-names>L.</given-names></name><name name-style="western"><surname>el Kheir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bucheton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mary</surname><given-names>C.</given-names></name><etal/></person-group><article-title>IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani</article-title><source>J. Clin. Invest.</source><year>2009</year><volume>119</volume><fpage>2379</fpage><lpage>2387</lpage><pub-id pub-id-type="doi">10.1172/JCI38813</pub-id><pub-id pub-id-type="pmid">19620772</pub-id><pub-id pub-id-type="pmcid">PMC2719936</pub-id></element-citation></ref><ref id="B83-microorganisms-08-01201"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Piccirillo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shevach</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name></person-group><article-title>CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells control Leishmania major persistence and immunity</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>502</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nature01152</pub-id><pub-id pub-id-type="pmid">12466842</pub-id></element-citation></ref><ref id="B84-microorganisms-08-01201"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Beverley</surname><given-names>S.M.</given-names></name></person-group><article-title>Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E801</fpage><lpage>E810</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619265114</pub-id><pub-id pub-id-type="pmid">28096392</pub-id><pub-id pub-id-type="pmcid">PMC5293024</pub-id></element-citation></ref><ref id="B85-microorganisms-08-01201"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bouladoux</surname><given-names>N.</given-names></name></person-group><article-title>Parasites and immunoregulatory T cells</article-title><source>Curr. Opin. Immunol.</source><year>2006</year><volume>18</volume><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2006.05.014</pub-id><pub-id pub-id-type="pmid">16766171</pub-id></element-citation></ref><ref id="B86-microorganisms-08-01201"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name></person-group><article-title>Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice</article-title><source>J. Immunol.</source><year>2005</year><volume>174</volume><fpage>2934</fpage><lpage>2941</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.5.2934</pub-id><pub-id pub-id-type="pmid">15728505</pub-id></element-citation></ref><ref id="B87-microorganisms-08-01201"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reckling</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Piccirillo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name></person-group><article-title>Role for CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity</article-title><source>J. Exp. Med.</source><year>2004</year><volume>200</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1084/jem.20040298</pub-id><pub-id pub-id-type="pmid">15263027</pub-id><pub-id pub-id-type="pmcid">PMC2212012</pub-id></element-citation></ref><ref id="B88-microorganisms-08-01201"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Von Stebut</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Caler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Udey</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>CD8<sup>+</sup> T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major</article-title><source>J. Immunol.</source><year>2002</year><volume>168</volume><fpage>3992</fpage><lpage>4000</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.8.3992</pub-id><pub-id pub-id-type="pmid">11937556</pub-id></element-citation></ref><ref id="B89-microorganisms-08-01201"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Timms</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>R&#246;llinghoff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lohoff</surname><given-names>M.</given-names></name></person-group><article-title>Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice</article-title><source>Infect. Immun.</source><year>1998</year><volume>66</volume><fpage>3968</fpage><lpage>3970</lpage><pub-id pub-id-type="doi">10.1128/IAI.66.8.3968-3970.1998</pub-id><pub-id pub-id-type="pmid">9673288</pub-id><pub-id pub-id-type="pmcid">PMC108466</pub-id></element-citation></ref><ref id="B90-microorganisms-08-01201"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzonna</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8<sup>+</sup> T cells</article-title><source>J. Exp. Med.</source><year>2004</year><volume>199</volume><fpage>1559</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1084/jem.20040172</pub-id><pub-id pub-id-type="pmid">15184505</pub-id><pub-id pub-id-type="pmcid">PMC2211781</pub-id></element-citation></ref><ref id="B91-microorganisms-08-01201"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okwor</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Onyilagha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Uzonna</surname><given-names>J.E.</given-names></name></person-group><article-title>CD8<sup>+</sup> T cells Are Preferentially Activated during Primary Low Dose Leishmania major Infection but Are Completely Dispensable during Secondary Anti-Leishmania Immunity</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e3300</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003300</pub-id><pub-id pub-id-type="pmid">25412267</pub-id><pub-id pub-id-type="pmcid">PMC4238992</pub-id></element-citation></ref><ref id="B92-microorganisms-08-01201"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#233;ndez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>Optimization of DNA vaccination against cutaneous leishmaniasis</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>3702</fpage><lpage>3708</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00376-6</pub-id><pub-id pub-id-type="pmid">12399198</pub-id></element-citation></ref><ref id="B93-microorganisms-08-01201"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurunathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stobie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Prussin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Glaichenhaus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fowell</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Locksley</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Requirements for the Maintenance of Th1 Immunity In Vivo Following DNA Vaccination: A Potential Immunoregulatory Role for CD8+ T Cells</article-title><source>J. Immunol.</source><year>2000</year><volume>165</volume><fpage>915</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.2.915</pub-id><pub-id pub-id-type="pmid">10878366</pub-id></element-citation></ref><ref id="B94-microorganisms-08-01201"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jayakumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Goldsmith-Pestana</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dondji</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lambris</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>McMahon-Pratt</surname><given-names>D.</given-names></name></person-group><article-title>Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation</article-title><source>Eur. J. Immunol.</source><year>2010</year><volume>40</volume><fpage>1355</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1002/eji.200939455</pub-id><pub-id pub-id-type="pmid">20213734</pub-id><pub-id pub-id-type="pmcid">PMC2944234</pub-id></element-citation></ref><ref id="B95-microorganisms-08-01201"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>F.Y.</given-names></name></person-group><article-title>Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to <italic toggle="yes">Leishmania tropica</italic></article-title><source>J. Exp. Med.</source><year>1981</year><volume>153</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1084/jem.153.3.557</pub-id><pub-id pub-id-type="pmid">6454739</pub-id><pub-id pub-id-type="pmcid">PMC2186105</pub-id></element-citation></ref><ref id="B96-microorganisms-08-01201"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Handman</surname><given-names>E.</given-names></name></person-group><article-title><italic toggle="yes">Leishmania tropica</italic> major in mice: Vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility</article-title><source>Aust. J. Exp. Biol. Med. Sci.</source><year>1983</year><volume>61</volume><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/icb.1983.2</pub-id><pub-id pub-id-type="pmid">6870673</pub-id></element-citation></ref><ref id="B97-microorganisms-08-01201"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woelbing</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kostka</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Moelle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sunderkoetter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waisman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nigg</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Knop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Udey</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity</article-title><source>J. Exp. Med.</source><year>2006</year><volume>203</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1084/jem.20052288</pub-id><pub-id pub-id-type="pmid">16418399</pub-id><pub-id pub-id-type="pmcid">PMC2118064</pub-id></element-citation></ref><ref id="B98-microorganisms-08-01201"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wylie</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Carbonell-Anto&#241;anzas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aiassa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dhollander</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zagmutt</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Brodbelt</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Solano-Gallego</surname><given-names>L.</given-names></name></person-group><article-title>A systematic review of the efficacy of prophylactic control measures for naturally-occurring canine leishmaniosis, part I: Vaccinations</article-title><source>Prev. Vet. Med.</source><year>2014</year><volume>117</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.prevetmed.2014.06.015</pub-id><pub-id pub-id-type="pmid">25074635</pub-id></element-citation></ref><ref id="B99-microorganisms-08-01201"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Possibilities and challenges for developing a successful vaccine for leishmaniasis</article-title><source>Parasit Vectors</source><year>2016</year><volume>9</volume><fpage>277</fpage><pub-id pub-id-type="doi">10.1186/s13071-016-1553-y</pub-id><pub-id pub-id-type="pmid">27175732</pub-id><pub-id pub-id-type="pmcid">PMC4866332</pub-id></element-citation></ref><ref id="B100-microorganisms-08-01201"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vouldoukis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>V.</given-names></name><name name-style="western"><surname>McGahie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cuisinier</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Gueguen</surname><given-names>S.</given-names></name></person-group><article-title>Use of a LiESP/QA-21 Vaccine (CaniLeish) Stimulates an Appropriate Th1-Dominated Cell-Mediated Immune Response in Dogs</article-title><source>PLoS Negl. Trop. Dis.</source><year>2012</year><volume>6</volume><elocation-id>e1683</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001683</pub-id><pub-id pub-id-type="pmid">22724031</pub-id><pub-id pub-id-type="pmcid">PMC3378610</pub-id></element-citation></ref><ref id="B101-microorganisms-08-01201"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez Cotrina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Iniesta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Monroy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Baz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hugnet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mara&#241;on</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fabra</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#243;mez-Nieto</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>C.</given-names></name></person-group><article-title>A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend<sup>&#174;</sup> against canine leishmaniosis</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>1972</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.111</pub-id><pub-id pub-id-type="pmid">29525281</pub-id></element-citation></ref><ref id="B102-microorganisms-08-01201"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petitdidier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pagniez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Papierok</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vincendeau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lemesre</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Bras-Gon&#231;alves</surname><given-names>R.</given-names></name></person-group><article-title>Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004614</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004614</pub-id><pub-id pub-id-type="pmid">27223609</pub-id><pub-id pub-id-type="pmcid">PMC4880307</pub-id></element-citation></ref><ref id="B103-microorganisms-08-01201"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roatt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Aguiar-Soares</surname><given-names>R.D.d.O.</given-names></name><name name-style="western"><surname>Vitoriano-Souza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coura-Vital</surname><given-names>W.</given-names></name><name name-style="western"><surname>Braga</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Corr&#234;a-Oliveira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martins-Filho</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Teixeira-Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Lana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gontijo</surname><given-names>N.F.</given-names></name><etal/></person-group><article-title>Performance of LBSap Vaccine after Intradermal Challenge with <italic toggle="yes">L. infantum</italic> and Saliva of Lu. longipalpis: Immunogenicity and Parasitological Evaluation</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e49780</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0049780</pub-id><pub-id pub-id-type="pmid">23189161</pub-id><pub-id pub-id-type="pmcid">PMC3506642</pub-id></element-citation></ref><ref id="B104-microorganisms-08-01201"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Resende</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Aguiar-Soares</surname><given-names>R.D.</given-names></name></person-group><article-title>de O.; Gama-Ker, H.; Roatt, B.M.; Mendon&#231;a, L.Z. de; Alves, M.L.R.; Silveira-Lemos, D. da; Corr&#234;a-Oliveira, R.; Martins-Filho, O.A.; Ara&#250;jo, M.S.S.; et al. Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after <italic toggle="yes">Leishmania chagasi</italic>-Challenge</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0161169</elocation-id><pub-id pub-id-type="pmid">27556586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0161169</pub-id><pub-id pub-id-type="pmcid">PMC4996460</pub-id></element-citation></ref><ref id="B105-microorganisms-08-01201"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boussoffara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kishi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamana</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ezzati</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khadem</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4<sup>+</sup> T cells</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>310ra167</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aac5477</pub-id><pub-id pub-id-type="pmid">26491077</pub-id></element-citation></ref><ref id="B106-microorganisms-08-01201"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Glennie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uzonna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>Intradermal Synthetic DNA Vaccination Generates Leishmania-Specific T Cells in the Skin and Protection against Leishmania major</article-title><source>Infect. Immun.</source><year>2019</year><volume>87</volume><fpage>e00227-e19</fpage><pub-id pub-id-type="doi">10.1128/IAI.00227-19</pub-id><pub-id pub-id-type="pmid">31182618</pub-id><pub-id pub-id-type="pmcid">PMC6652766</pub-id></element-citation></ref><ref id="B107-microorganisms-08-01201"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamakh-Ayari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bras-Gon&#231;alves</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bahi-Jaber</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petitdidier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Markikou-Ouni</surname><given-names>W.</given-names></name><name name-style="western"><surname>Aoun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>H.</given-names></name><etal/></person-group><article-title>In Vitro Evaluation of a Soluble Leishmania Promastigote Surface Antigen as a Potential Vaccine Candidate against Human Leishmaniasis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e92708</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092708</pub-id><pub-id pub-id-type="pmid">24786587</pub-id><pub-id pub-id-type="pmcid">PMC4008367</pub-id></element-citation></ref><ref id="B108-microorganisms-08-01201"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mistry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keding</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gabe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>E.</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Marco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colloca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siani</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005527</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005527</pub-id><pub-id pub-id-type="pmid">28498840</pub-id><pub-id pub-id-type="pmcid">PMC5443534</pub-id></element-citation></ref><ref id="B109-microorganisms-08-01201"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roatt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Aguiar-Soares RD de</surname><given-names>O.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>L.E.S.</given-names></name><name name-style="western"><surname>Cardoso JM de</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mathias</surname><given-names>F.A.S.</given-names></name><name name-style="western"><surname>de Brito</surname><given-names>R.C.F.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Gontijo</surname><given-names>N.D.F.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>S.d.A.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00217</pub-id><pub-id pub-id-type="pmid">28321217</pub-id><pub-id pub-id-type="pmcid">PMC5338076</pub-id></element-citation></ref><ref id="B110-microorganisms-08-01201"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayrink</surname><given-names>W.</given-names></name><name name-style="western"><surname>Magalhaes</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Michalick</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>A.d.O.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Genaro</surname><given-names>O.</given-names></name></person-group><article-title>Immunotherapy as a treatment of American cutaneous leishmaniasis: Preliminary studies in Brazil</article-title><source>Parassitologia</source><year>1992</year><volume>34</volume><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">1339971</pub-id></element-citation></ref><ref id="B111-microorganisms-08-01201"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamshidi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avizeh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mohebali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bokaie</surname><given-names>S.</given-names></name></person-group><article-title>Immunotherapy Using Autoclaved, L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis</article-title><source>Iran. J. Parasitol.</source><year>2011</year><volume>6</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">22347294</pub-id><pub-id pub-id-type="pmcid">PMC3279897</pub-id></element-citation></ref><ref id="B112-microorganisms-08-01201"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toepp</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grinnage-Pulley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leal-Lima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>6433</fpage><lpage>6441</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.08.087</pub-id><pub-id pub-id-type="pmid">30219369</pub-id></element-citation></ref><ref id="B113-microorganisms-08-01201"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinzel</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Schoenhaut</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Rerko</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Rosser</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Gately</surname><given-names>M.K.</given-names></name></person-group><article-title>Recombinant interleukin 12 cures mice infected with Leishmania major</article-title><source>J. Exp. Med.</source><year>1993</year><volume>177</volume><fpage>1505</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1084/jem.177.5.1505</pub-id><pub-id pub-id-type="pmid">8097524</pub-id><pub-id pub-id-type="pmcid">PMC2191017</pub-id></element-citation></ref><ref id="B114-microorganisms-08-01201"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montakhab-Yeganeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abdossamadi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zahedifard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Taslimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Badirzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saljoughian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Taghikhani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S.</given-names></name></person-group><article-title>Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against Leishmania major-infected BALB/c mice</article-title><source>Parasite Immunol.</source><year>2017</year><volume>39</volume><fpage>e12461</fpage><pub-id pub-id-type="doi">10.1111/pim.12461</pub-id><pub-id pub-id-type="pmid">28833211</pub-id></element-citation></ref><ref id="B115-microorganisms-08-01201"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayakar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandrasekaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veronica</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bharadwaja</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maurya</surname><given-names>R.</given-names></name></person-group><article-title>Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>14664</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-15288-7</pub-id><pub-id pub-id-type="pmid">29116252</pub-id><pub-id pub-id-type="pmcid">PMC5676676</pub-id></element-citation></ref><ref id="B116-microorganisms-08-01201"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Fonseca-Martins</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Pratti</surname><given-names>J.E.S.</given-names></name><name name-style="western"><surname>Firmino-Cruz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>D.C.O.</given-names></name><name name-style="western"><surname>Soong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>de Guedes</surname><given-names>H.L.d.M.</given-names></name></person-group><article-title>Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis -infected BALB/c mice reduce parasite load</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>20275</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-56336-8</pub-id><pub-id pub-id-type="pmid">31889072</pub-id><pub-id pub-id-type="pmcid">PMC6937231</pub-id></element-citation></ref><ref id="B117-microorganisms-08-01201"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quirino</surname><given-names>G.F.S.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>M.S.L.</given-names></name><name name-style="western"><surname>Davoli-Ferreira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sacramento</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>M.H.F.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Carregaro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.S.</given-names></name></person-group><article-title>Interleukin-27 (IL-27) Mediates Susceptibility to Visceral Leishmaniasis by Suppressing the IL-17&#8211;Neutrophil Response</article-title><source>Infect. Immun.</source><year>2016</year><volume>84</volume><fpage>2289</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1128/IAI.00283-16</pub-id><pub-id pub-id-type="pmid">27245409</pub-id><pub-id pub-id-type="pmcid">PMC4962641</pub-id></element-citation></ref><ref id="B118-microorganisms-08-01201"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loka</surname><given-names>R.K.P.</given-names></name><name name-style="western"><surname>Dandekar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>B.</given-names></name></person-group><article-title>Inhibition of IL-2 Induced IL-10 Production as a Principle of Phase-Specific Immunotherapy</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>4636</fpage><lpage>4643</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.7.4636</pub-id><pub-id pub-id-type="pmid">16982902</pub-id></element-citation></ref><ref id="B119-microorganisms-08-01201"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maurya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nyl&#233;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>IL-10 Neutralization Promotes Parasite Clearance in Splenic Aspirate Cells From Patients With Visceral Leishmaniasis</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>1134</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir461</pub-id><pub-id pub-id-type="pmid">21881130</pub-id><pub-id pub-id-type="pmcid">PMC3164427</pub-id></element-citation></ref><ref id="B120-microorganisms-08-01201"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadem</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feiz Barazandeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Keynan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Uzonna</surname><given-names>J.E.</given-names></name></person-group><article-title>Pharmacological inhibition of p110&#948; subunit of PI3K confers protection against experimental leishmaniasis</article-title><source>J. Antimicrob. Chemother.</source><year>2017</year><volume>72</volume><fpage>467</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw448</pub-id><pub-id pub-id-type="pmid">27999013</pub-id></element-citation></ref><ref id="B121-microorganisms-08-01201"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadir</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shaler</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Oryan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rudak</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Mazzuca</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dikeakos</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Haeryfar</surname><given-names>S.M.M.</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S.</given-names></name></person-group><article-title>Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><elocation-id>e0006701</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006701</pub-id><pub-id pub-id-type="pmid">30133440</pub-id><pub-id pub-id-type="pmcid">PMC6122837</pub-id></element-citation></ref><ref id="B122-microorganisms-08-01201"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baranowski</surname><given-names>M.</given-names></name></person-group><article-title>Biological role of liver x receptors</article-title><source>J. Physiol. Pharmacol.</source><year>2008</year><volume>59</volume><fpage>31</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">19258656</pub-id></element-citation></ref><ref id="B123-microorganisms-08-01201"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruhn</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Marathe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maretti-Mira</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haskell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Vanchinathan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Tontonoz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>LXR Deficiency Confers Increased Protection against Visceral Leishmania Infection in Mice</article-title><source>PLoS Negl. Trop. Dis.</source><year>2010</year><volume>4</volume><elocation-id>e886</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000886</pub-id><pub-id pub-id-type="pmid">21103366</pub-id><pub-id pub-id-type="pmcid">PMC2982826</pub-id></element-citation></ref><ref id="B124-microorganisms-08-01201"><label>124.</label><element-citation publication-type="web"><article-title>Aryl Hydrocarbon Receptor-Signaling Regulates Early Leishmania Major-Induced Cytokine Expression&#8212;Abstract&#8212;Europe PMC [Internet]</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://europepmc.org/article/PMC/6843081">https://europepmc.org/article/PMC/6843081</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-07">(accessed on 7 May 2020)</date-in-citation></element-citation></ref><ref id="B125-microorganisms-08-01201"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zayats</surname><given-names>R.</given-names></name><name name-style="western"><surname>Viana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boaventura</surname><given-names>V.</given-names></name><name name-style="western"><surname>Murooka</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The Long Pentraxin 3 (PTX3) Suppresses Immunity to Cutaneous Leishmaniasis by Negatively Regulating Th17 Response</article-title><source>Cell Rep.</source><year>2020</year><comment>in revision</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108513</pub-id><pub-id pub-id-type="pmid">33326783</pub-id></element-citation></ref><ref id="B126-microorganisms-08-01201"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeogu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Edechi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Akaluka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Feiz-Barazandeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zayats</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salako</surname><given-names>E.</given-names></name><name name-style="western"><surname>Onyilagha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Semaphorin 3E promotes susceptibility to Leishmania major infection in mice by suppressing CD4+ Th1 cell response</article-title><source>J. Immunol.</source><year>2020</year><comment>in revision</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2000516</pub-id><pub-id pub-id-type="pmid">33443083</pub-id></element-citation></ref><ref id="B127-microorganisms-08-01201"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>L.F.M.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>D.F.H.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Pinho</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Werneck</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Khouri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Barral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barral-Netto</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in <italic toggle="yes">L. infantum</italic>-infected dogs</article-title><source>Vaccine X.</source><year>2020</year><volume>4</volume><fpage>100048</fpage><pub-id pub-id-type="doi">10.1016/j.jvacx.2019.100048</pub-id><pub-id pub-id-type="pmid">31891152</pub-id><pub-id pub-id-type="pmcid">PMC6928333</pub-id></element-citation></ref><ref id="B128-microorganisms-08-01201"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>S.</given-names></name></person-group><article-title>Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>5625</fpage><lpage>5629</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.11.5625</pub-id><pub-id pub-id-type="pmid">12759442</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="microorganisms-08-01201-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Graphical illustration of the immune response against <italic toggle="yes">Leishmania</italic> infection and some immunotherapeutic strategies to target key immune cells and molecules for treatment of Leishmaniasis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-08-01201-g001.jpg"/></fig><table-wrap id="microorganisms-08-01201-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-08-01201-t001_Table 1</object-id><label>Table 1</label><caption><p>Advances in vaccination against leishmaniasis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Candidate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Quality of Protection/Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Host</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference(s)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CaniLeish<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fractionated </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-microorganisms-08-01201" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leishmune<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fractionated </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-microorganisms-08-01201" ref-type="bibr">98</xref>,<xref rid="B99-microorganisms-08-01201" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LiESP/QA-21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-microorganisms-08-01201" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LetiFend<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant protein </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/<italic toggle="yes">L. infantum</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-microorganisms-08-01201" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ES <italic toggle="yes">La</italic>PSA-38S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good prophylactic vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-microorganisms-08-01201" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LBSap vaccine (<italic toggle="yes">L. brazilliensis</italic> antigen &amp; saponin adjuvant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fractionated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/cross-protection (<italic toggle="yes">L. infantum)</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-microorganisms-08-01201" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LbSapSal vaccine (<italic toggle="yes">L. brazilliensis</italic> antigen + saponin + <italic toggle="yes">lutzomiyia longpalpis</italic> salivary gland extract)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fractionated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/cross protection (<italic toggle="yes">L. chagasi)</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-microorganisms-08-01201" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leishmania glycosomal PEPCK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant protein </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/cross protection <italic toggle="yes">(L. major, L. donovani</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-microorganisms-08-01201" ref-type="bibr">105</xref>,<xref rid="B106-microorganisms-08-01201" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promastigote Surface Antigen (PSA) from <italic toggle="yes">L. amazonensis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/<italic toggle="yes">L. amazonensis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human T cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-microorganisms-08-01201" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAd63-KH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/<italic toggle="yes">L. donovani</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human (Clinical trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-microorganisms-08-01201" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">L. bralizilliensis</italic> antigen + monophosphoryl lipid A (MPL) adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good/<italic toggle="yes">L. infantum</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-microorganisms-08-01201" ref-type="bibr">109</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="microorganisms-08-01201-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-08-01201-t002_Table 2</object-id><label>Table 2</label><caption><p>Advances in immunotherapy against leishmaniasis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Agent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Host</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference(s)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Leishmania</italic> + <italic toggle="yes">M. vaccae</italic> + Meglumine antimoniate </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective treatment of cutaneous leishmaniasis; not as effective as glucantime</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-microorganisms-08-01201" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant IL-12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promoted parasite clearance and induced protective immunity against <italic toggle="yes">L. major</italic> challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-microorganisms-08-01201" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant CXCL-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly decreased parasite burden, increased NO production and Th1 response </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-microorganisms-08-01201" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-PD-1 and anti-PD-L1 monoclonal antibodies </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased induction of protective immune cells resulting in lower parasite burden</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-microorganisms-08-01201" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-2 and IL-10 blockade by monoclonal antibody treatment </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effectively restored the host&#8217;s T cell functions leading to reduced parasite burdens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-microorganisms-08-01201" ref-type="bibr">118</xref>,<xref rid="B119-microorganisms-08-01201" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAL-101 (p110&#948;- inhibitor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced parasite burden in cutaneous lesions, spleens, and liver </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-microorganisms-08-01201" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSK-2126458 and rapamycin (m-Tor inhibitor) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapy </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controlled disease progression and reduced parasite burden</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-microorganisms-08-01201" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver X receptors deletion </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced parasite burden in liver</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-microorganisms-08-01201" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentraxin-3 (PTX-3) gene deletion </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced cutaneous lesion and parasite burden by enhancing Th17/I17 response </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-microorganisms-08-01201" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semaphorin-3E gene deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced cutaneous lesion and parasite burden by increasing Th1 response </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-microorganisms-08-01201" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allopurinol &amp; <italic toggle="yes">Leishmania</italic> vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy + chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clearance of <italic toggle="yes">L. infantum</italic> and long-lasting immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-microorganisms-08-01201" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soluble <italic toggle="yes">L. donovani</italic> antigen (SLDA) pulsed-BMDCs &amp; sodium antimony gluconate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy + chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete parasite clearance from liver and spleens </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-microorganisms-08-01201" ref-type="bibr">128</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>